


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:05:17Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406448" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406448</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>bmcneul</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Neurol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Neurol</journal-id><journal-id journal-id-type="pmc-domain-id">48</journal-id><journal-id journal-id-type="pmc-domain">bmcneul</journal-id><journal-title-group><journal-title>BMC Neurology</journal-title></journal-title-group><issn pub-type="epub">1471-2377</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406448</article-id><article-id pub-id-type="pmcid-ver">PMC12406448.1</article-id><article-id pub-id-type="pmcaid">12406448</article-id><article-id pub-id-type="pmcaiid">12406448</article-id><article-id pub-id-type="pmid">40898070</article-id><article-id pub-id-type="doi">10.1186/s12883-025-04379-y</article-id><article-id pub-id-type="publisher-id">4379</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Association between low-grade inflammation and distal sensorimotor polyneuropathy in type 2 diabetes: a cross-sectional study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="S">Sihua</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lan</surname><given-names initials="Y">Yan</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zheng</surname><given-names initials="C">Cheng</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liang</surname><given-names initials="H">Hongyun</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wei</surname><given-names initials="Y">Yanhong</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Chen</surname><given-names initials="B">Bing</given-names></name><address><email>cb77182@163.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03dveyr97</institution-id><institution-id institution-id-type="GRID">grid.256607.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 1798 2653</institution-id><institution>Department of Endocrinology, Wuming Hospital, </institution><institution>affiliated with Guangxi Medical University, </institution></institution-wrap>Nanning, Guangxi China </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>25</volume><issue-id pub-id-type="pmc-issue-id">478179</issue-id><elocation-id>378</elocation-id><history><date date-type="received"><day>22</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>31</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="12883_2025_Article_4379.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">As inflammatory processes may be involved in the pathogenesis of diabetic distal sensorimotor polyneuropathy (DSPN), the first aim of the present study was to determine the clinical characteristics of type 2 diabetes mellitus (T2DM) with distal sensorimotor polyneuorpathy (DSPN). Next goal was to investigate inflammatory biomarkers, insulin-like growth factor- 1 and lipid profile in these patients. Finally, we aimed to compare the renal function in these patients.</p></sec><sec><title>Methods</title><p id="Par2">In a cross-sectional study, we included 160 patients diagnosed with T2DM. The control group was included 22 non-diabetic healthy subjects (HC). The patients with diabetes were divided into four groups, absent (<italic toggle="yes">n</italic>&#8201;=&#8201;74), mild (<italic toggle="yes">n</italic>&#8201;=&#8201;38), moderate (<italic toggle="yes">n</italic>&#8201;=&#8201;24), and severe (<italic toggle="yes">n</italic>&#8201;=&#8201;24) using a nomogram based on the MNSI features for a DSPN severity grading probability.</p></sec><sec><title>Results</title><p id="Par3">Patients with moderate and severe DSPN were a little older and had longer duration of diabetes compared to patients with absent and mild DSPNS (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05). Serum levels of interferon-gamma (INF-&#947;), interleukin (IL)-1&#946;, IL-4, IL- 6 levels in patients with severe DSPN were significantly higher than HC, absent, mild and moderate of DSPN (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05). The circulating levels of insulin-like growth factor-1 (IGF-1) were significantly lower in patients with severe DSPN (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) compared to absent, mild and moderate of DSPN and HC. Diabetic patients with moderate DSPN showed increased circulating levels of TC, LDL-C, APOB (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) compared to HC and patients with absent, mild and severe DSPN. Moreover, APO-A1/APOB was significantly lower in patients with diabetes compared to HC. In addition, patients with severe DSPN showed increased Cystatin C (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) compared to HC and absent, mild, and moderate DSPN. Multivariate ordered logistic regression analysis showed that the levels of IL-6 (OR&#8201;=&#8201;3.166, 95%CI 1.461&#8211;6.860, <italic toggle="yes">p</italic>&#8201;=&#8201;0.003, IL-1&#946;(OR&#8201;=&#8201;1.148, 95%CI 1.070&#8211;2.232; <italic toggle="yes">p</italic>&#8201;=&#8201;0.000), TC (OR&#8201;=&#8201;1.174, 95%CI 1.011&#8211;1.364; <italic toggle="yes">p</italic>&#8201;=&#8201;0.035), LDL-C (OR&#8201;=&#8201;1.246, 95%CI 1.098&#8211;3.618; <italic toggle="yes">p</italic>&#8201;=&#8201;0.003), Cystatin C (OR&#8201;=&#8201;1.867, 95%CI 1.245&#8211;3.434; <italic toggle="yes">p</italic>&#8201;=&#8201;0.004), ages (OR&#8201;=&#8201;1.043, 95%CI 1.009&#8211;1.078; <italic toggle="yes">p</italic>&#8201;=&#8201;0.012), and duration of diabetes (OR&#8201;=&#8201;1.157, 95%CI 1.049&#8211;1.277; <italic toggle="yes">p</italic>&#8201;=&#8201;0.004) were positively associated with increasing the odds ration of DSPN in T2DM. Conversely, the level of IGF-1 (OR&#8201;=&#8201;0.922, 95%CI 0.961&#8211;0.982; <italic toggle="yes">p</italic>&#8201;=&#8201;0.000) and ratio of APO-A1/APOB (OR&#8201;=&#8201;0.212, 95%CI 0.078&#8211;0.567; <italic toggle="yes">p</italic>&#8201;=&#8201;0.002) were significantly associated with decreasing the odds ratio of DSPN in T2DM.</p></sec><sec><title>Conclusions</title><p id="Par4">The levels of inflammatory biomarkers such as INF-&#947;, IL-1&#946;, IL-4, IL- 6 were increased in patients with severe DSPN in T2DM. Ages, duration of diabetes as well as high circulating levels of IL-6, IL-1&#946;, TC, LDL-C and Cystatin C were positively associated with DSPN in T2DM. Conversely, the level of IGF-1 and the ratio of APOA1/APOB were independent protective factors for DSPN in T2DM. Our results emphasize the importance of addressing issues related to inflammatory biomarkers, lipids and early impaired renal function in T2DM with DSPN, as these may be of potential relevance for deteriorating DSPN.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Inflammatory biomarkers</kwd><kwd>Insulin-like growth factor-1</kwd><kwd>Type 2 diabetes mellitus</kwd><kwd>Distal sensorimotor polyneuropathy</kwd><kwd>Lipids</kwd><kwd>MNSI</kwd></kwd-group><funding-group><award-group><funding-source><institution>Dr. BC was supported by a research grant from scientific research and technology development plan project in Wuming district, Nanning city, Guangxi, China</institution></funding-source><award-id>WM20190404</award-id><principal-award-recipient><name name-style="western"><surname>Chen</surname><given-names>Bing</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par22">Diabetes mellitus (DM) has emerged as one of the most serious and common chronic diseases at the present time, causing life threatening disabling and complications, and reducing life expectancy [<xref ref-type="bibr" rid="CR1">1</xref>]. The global prevalence of diabetes mellitus (DM) in 20&#8211;79 years in 2021 was estimated to be 10.5% (536.6 million people), projecting to 12.2% (783.2 million) in 2045 [<xref ref-type="bibr" rid="CR2">2</xref>]. Thus, the prevalence of the complication of diabetes would be increased concomitantly [<xref ref-type="bibr" rid="CR2">2</xref>]. Distal sensorimotor polyneuropathy (DSPN) represents the most common diabetic microvascular complication, affecting at least one-third of patients with type 2 diabetes mellitus (T2DM) [<xref ref-type="bibr" rid="CR3">3</xref>]. Small and large peripheral nerve fibers can be involved in DSPN. Large nerve fiber damage causes paresthesia, sensory loss and muscle weakness, and small nerve fiber damage is associated with pain, anesthesia, foot ulcer and autonomic symptoms. However, the exact pathogenesis behind peripheral polyneuropathy in diabetes remains a matter of debate, but a multifactorial course of events is likely [<xref ref-type="bibr" rid="CR3">3</xref>]. There is a growing number of evidence indicating that inflammatory processes play an important role in diabetic neuropathy. A study included 157 participants with and without diabetic neuropathy, and 55 healthy controls reported that serum levels of inflammatory cytokines, including tumor necrosis factor-&#945; (TNF-&#945;) and C-reactive protein (CRP) were increased in subjects with diabetic neuropathy [<xref ref-type="bibr" rid="CR4">4</xref>]. In a small cross-sectional study, researchers showed that elevated serum levels of IL-6 and IL-10 in patients with pre-diabetes and T2DM correlated with markers of large nerve fiber sensory and motor axonal damage and with signs of motor nerve demyelination [<xref ref-type="bibr" rid="CR5">5</xref>]. A series of investigations based on MONIKA/KORA Survey F3 and KORA F4 studies indicated that DSPN was associated with increased circulating concentrations of several inflammatory markers [<xref ref-type="bibr" rid="CR6">6</xref>&#8211;<xref ref-type="bibr" rid="CR8">8</xref>]. Although, the above-mentioned studies have revealed that inflammatory biomarkers abnormalities were associated with DSPN in T2DM. The levels of these systemic cytokines are differential and unspecific. In fact, the inflammatory biomarkers data involved in T2DM with DSPN progression are limited.</p><p id="Par23">Insulin-like growth factor 1 (IGF-1) is a pluripotent growth factor with multiple functions in the peripheral and central nervous system. It supports neuronal survival and axon growth, and also acts on myelinating, Schwann cells and oligodendroglia. In diabetic mice, IGF-1 exerts a protective effect against peripheral neuropathy [<xref ref-type="bibr" rid="CR9">9</xref>]. Previous study was demonstrated that sciatic nerve mRNA expression of IGF-1 is delayed and attenuated in type 1 diabetes mellitus (T1DM) [<xref ref-type="bibr" rid="CR10">10</xref>]. However, this response following nerve damage is significantly less perturbed in T2DM compared to T1DM [<xref ref-type="bibr" rid="CR11">11</xref>]. Studies were reported significant decreases in the circulating levels of IGF-1 in T1DM patients when neuropathic complications were most prominent [<xref ref-type="bibr" rid="CR12">12</xref>]. However, there are few comparative reports regarding IGF-1 in T2DM patients with DSPN progression.</p><p id="Par24">The aim of this study was to investigate the level of inflammatory biomarkers and IGF-1 in T2DM with DSPN. Next goal was to investigate differences in metabolic status, and early renal function parameter between non-diabetic healthy subjects (HC) and T2DM patients with DSPN.</p></sec><sec id="Sec2"><title>Subjects and methods</title><sec id="Sec3"><title>Study population</title><p id="Par25">This is cross-sectional study involving subjects with and without T2DM, and that participants with T2DM were evaluated for DSPN and classified as absent, mild, moderate, or severe. 206 patients with T2DM were consecutively recruited from the endocrine inpatient clinics at Wuming hospital, Guangxi Medical University between May 2022 and September 2023. This study was approved by Wuming Hospital Ethics Committee and was performed in accordance with the Declaration of Helsinki. Diagnosis of DM is according to the criteria of the American Diabetes Association (ADA) [<xref ref-type="bibr" rid="CR13">13</xref>]. Participants with T2DM were excluded if they were pregnancy, T1DM, history of major cardiac, cerebral, peripheral vascular diseases, congestive heart diseases, hepatic diseases, positive HIV serology, thrombotic diseases, alcoholism, hypothyroidism, vitamin B12 deficiency, leprosy, lactation, use of neurotoxic drugs, cancer, acute infections or chronic inflammatory diseases, which could affect the circulating levels of inflammatory biomarkers. 30 participants with non-diabetic healthy subjects were included as control group (HC). For the HC, participants with neurological alterations were excluded. All participants then received anthropometric measures (Height, weight, blood pressure), detailed biochemical and hematological tests including fasting glucose, glycosylated hemoglobin (HbA1c), Cystatin C (CysC), lipids profile [total cholesterol(TC), high density lipoprotein cholesterol -C (HDL-C), low density lipoprotein cholesterol -C (LDL-C), triglyceride (TG), apolipoprotein-a1 (APO-A1), apolipoprotein-b (APOB)], inflammatory biomarkers[TNF-&#593;, interferon-&#947; (INF-&#947;), interlukin-1&#946;, 2, 4, 6, 10, high -sensitivity C-reactive protein(hs-CRP)] and IGF-1. Participants who had incomplete data in the above tests were excluded. Then, Michigan Neuropathy Screening Instrument (MNSI) was performed to assess neuropathy in participants with T2DM. A workflow of the selection process of participants and the number of participants were presented in figure <xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Workflow of the selected participant. Participants were screened for DSPN and classified the severity of DSPN base on MNSI variables score from the generated nomogram. HbA1C: glycated hemoglobin; CysC: Cystatin C; TNF-&#945;: tumor necrosis factor- &#945;; INF-&#947;: interferon-&#947;; IL: interleukin; hs-CRP: high- sensitivity C-reactive protein; IGF-1: insulin- like growth factor-1; HDL: high density lipoprotein cholesterol; LDL: low density lipoprotein cholesterol; APO-A1: apolipoprotein-a1, APOB: apolipoprotein-b</p></caption><graphic id="MO1" position="float" orientation="portrait" xlink:href="12883_2025_4379_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec4"><title>Evaluation of distal sensorimotor polyneuropathy (DSPN)</title><p id="Par26">MNSI was used to assess neuropathy in participants with diabetes [<xref ref-type="bibr" rid="CR14">14</xref>]. Neuropathy symptoms were assessed from 15 yes/no questions and neuropathy signs were assessed from foot appearance (0 and 1 for normal or deformities, dry skin, callus, infection, fissure, or other irregularities, respectively), foot ulceration (0 and 1 for normal and abnormal, respectively), ankle reflexes (0, 0.5 and 1 for normal, reduced, and absent, respectively), thermal test (0 and 1 for normal and abnormal, respectively), vibration perception at the great toes using 128 Hz tuning fork (0, 0.5 and 1 for normal, reduced and abnormal, respectively), and tactile sensitivity using 10-gm monofilament test (0, 0.5 and 1 for normal, reduced, and absent, respectively). The 128 Hz tuning fork was performed by forcing the fork to vibrate on both sides, placing the patient on the wrist or thumb (Radius or medial malleolus) and asking them to report when the patient stops feeling the vibrations. Then the examiner rested the fork on the patient&#8217;s wrist and counted in seconds how long he still felt the vibrations. This was essentially the time during which the respondent&#8217;s sense was diminished. The test was performed bilaterally and recorded in a standardized form. Monofilament test was performed by asking the subject to turn his head to the side or to close his eyes so as not to watch the test being performed alone. A plastic filament (Adjusted to provide a pressured of 10 g) touches a total of 10 points on the subjects&#8217; feet, of which 9 were on the plantar side and 1 on the dorsal side of the foot. At least 8 out of 10 correct responses were considered to indicate normal sensibility. Less than eight perceived applications indicated reduced sensibility. If the result was negative at any point, sensibility to touch was considered absent [<xref ref-type="bibr" rid="CR15">15</xref>]. Patients with a screening value&#8201;&gt;&#8201;2 were considered neuropathy [<xref ref-type="bibr" rid="CR14">14</xref>]. However, there is controversy on the optimal cut-off value for identifying DSPN. Also, the MNSI lacks a standardized grading system for severity classification. Recently, a grading system from MNSI data was applied to identify DSPN severity probability developed by Haque F, et al. [<xref ref-type="bibr" rid="CR16">16</xref>]. A nomogram for predicting DSPN severity was formed utilizing the top seven MNSI features, namely vibration perception (R), 10-gm filament, previous diabetic neuropathy, vibration perception (L), appearance of callus, deformities and fissure [<xref ref-type="bibr" rid="CR16">16</xref>]. Patients were classified into four different classed of DSPN severity, namely absent, mild, moderate and severe, with cut-off values of 10.50, 12.70 and 15.00 based on the generated nomogram [<xref ref-type="bibr" rid="CR16">16</xref>]. Hence, according to the nomogram, 160 patients with T2DM in our study were divided into four groups: absent (<italic toggle="yes">n</italic>&#8201;=&#8201;74), mild (<italic toggle="yes">n</italic>&#8201;=&#8201;38), moderate (<italic toggle="yes">n</italic>&#8201;=&#8201;24), and severe (<italic toggle="yes">n</italic>&#8201;=&#8201;24) for a DSPN probability. Table <xref rid="Tab1" ref-type="table">1</xref> shows the MNSI responses and their corresponding score generated by the nomogram.</p><p id="Par27">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>MNSI variables score from the generated nomogram</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Top 7 MNSI variables</th><th align="left" colspan="1" rowspan="1">Response<break/>on MNSI</th><th align="left" colspan="1" rowspan="1">Corresponding<break/>Score</th></tr></thead><tbody><tr><td align="left" rowspan="5" colspan="1">10-gm filament</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">0.5</td><td align="left" colspan="1" rowspan="1">2.5</td></tr><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">5</td></tr><tr><td align="left" colspan="1" rowspan="1">1.5</td><td align="left" colspan="1" rowspan="1">7.5</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">10</td></tr><tr><td align="left" rowspan="3" colspan="1">Vibration perception (R)</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">0.5</td><td align="left" colspan="1" rowspan="1">2.4</td></tr><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">4.8</td></tr><tr><td align="left" rowspan="3" colspan="1">Vibration perception (L)</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">0.5</td><td align="left" colspan="1" rowspan="1">1.9</td></tr><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">3.8</td></tr><tr><td align="left" rowspan="2" colspan="1">Appearance of Deformities</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">4.8</td></tr><tr><td align="left" rowspan="2" colspan="1">Appearance of Callus</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">4.1</td></tr><tr><td align="left" rowspan="2" colspan="1">Previous Diabetic Neuropathic</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">2.1</td></tr><tr><td align="left" rowspan="2" colspan="1">Appearance of Fissure</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">5.2</td></tr></tbody></table><table-wrap-foot><p>Ref. [<xref ref-type="bibr" rid="CR16">16</xref>]</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec5"><title>Data collection</title><p id="Par28">Plasma specimens were collected from blood samples drawn in ethylenediaminetetraacetic acid (EDTA) tubes and stored at- 80 &#176;C prior to analysis. All samples were stored within 1 h after collection. CysC, fasting serum glucose, HbA1c, serum LDL-C, serum lipoprotein HDL-C, TC, TG, APO-A1, and APOB were measured using an auto-analyzer instrument (Cobas C, Roche, Germany).</p><p id="Par29">The weight and height of each participant were measured to calculate their body mass index (BMI). Blood pressure was recorded using an automatic BP monitor.</p></sec><sec id="Sec6"><title>Biochemical markers and IGF-1 tests</title><p id="Par30">We set out to measure 13 inflammatory markers. The concentrations of TNF-&#945;, IFN-&#945;, IFN-&#947;, IL &#8722;1&#946;, IL &#8722;2, IL &#8722;4, IL-5, IL &#8722;6, IL-8, IL &#8722;10, IL-12P70 and IL-17 in plasma samples were measured via flow cytometer using a Human Basic Kit Flow Cytomix (Raisecare Corporation, Qingdao, China), according to the manufacturer&#8217;s recommendations. Data acquisition and analysis were conducted via a BD FACSlyric flow cytometer (San Jose, USA). Serum hsCRP was determined using a particle-enhanced immunoturbidemetric assay on a Modular Analytics P800 apparatus (Roche Diagnosis). The concentration of IGF-1 was measured via Elecsys601 (Cobas E, Germany) using an insulin-like growth factor-1 kit (Roche, Shanghai, China).</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par31">Statistical analyses were performed with SPSS version 20.0 (IBM Corp. Armonk, NY). All variables followed a normal distribution. Normally distributed data was expressed as mean (&#177;&#8201;SD) values and compared using ANOVA and t-test procedures. The independent t-test was used for group comparisons. Categorical variables were expressed as frequencies and compared using the chi-square (<italic toggle="yes">&#967; 2</italic>) test. Multivariate ordered logistic regression analysis was used to assess association between DSPN severity, clinical characteristics and inflammatory biomarkers. G*Power version 3.1.9.7 (<ext-link ext-link-type="uri" xlink:href="http://www.psycho.uni-duesseldorf.de/abteilungen/aap/gpower3/">http://www.psycho.uni-duesseldorf.de/abteilungen/aap/gpower3/</ext-link>).</p><p id="Par32">was used for post-hoc sample size calculation. Statistical significance was assessed at a <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 level. Post-hoc sample size calculation revealed that <italic toggle="yes">n</italic>&#8201;=&#8201;258 patients with T2DM and <italic toggle="yes">n</italic>&#8201;=&#8201;36 HC should be included in our study assuming a large effect size. With <italic toggle="yes">n</italic>&#8201;=&#8201;22 HC and <italic toggle="yes">n</italic>&#8201;=&#8201;160 patients with T2DM, we performed an exploratory study.</p></sec></sec><sec id="Sec8"><title>Results</title><sec id="Sec9"><title>Clinical characteristics of study participants</title><p id="Par33">Demographic and clinical characteristics of study groups are summarized in Table <xref rid="Tab2" ref-type="table">2</xref>. When compared to HC, patients with diabetes were older, had higher fasting glucose, had higher HbA1c, and had higher diastolic blood pressure (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05). Moreover, patients with moderate and severe DSPN were a little older and had longer duration of diabetes compared to patients with absent and mild DSPN (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05). There were no significant differences in fasting glucose and HbA1c between patients without DSPN and with DSPN. Patients with mild and moderate DSPN were treated with oral hypoglycemic drugs. Most of patients with severe DSPN were treated with insulin in comparison to patients with absent, mild and moderate DSPN. In addition, patients with severe DSPN showed higher level of CysC (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05). There was no significant difference in BMI and systolic pressure between all the groups.</p><p id="Par34">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Characteristics of non-Diabetic healthy subjects (HC) and diabetes with absent, mild, moderate and severe DSPN</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">HC</th><th align="left" colspan="1" rowspan="1">Absent</th><th align="left" colspan="1" rowspan="1">Mild</th><th align="left" colspan="1" rowspan="1">Moderate</th><th align="left" colspan="1" rowspan="1">Severe</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;22</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;74</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;38</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;24</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;24</td></tr><tr><td align="left" colspan="1" rowspan="1">Age (years)</td><td align="left" colspan="1" rowspan="1">53&#8201;&#177;&#8201;15</td><td align="left" colspan="1" rowspan="1">57&#8201;&#177;&#8201;11<sup>*</sup></td><td align="left" colspan="1" rowspan="1">59&#8201;&#177;&#8201;11<sup>*</sup></td><td align="left" colspan="1" rowspan="1">63&#8201;&#177;&#8201;11<sup>*&#8225;</sup></td><td align="left" colspan="1" rowspan="1">65&#8201;&#177;&#8201;9<sup>* &#8225;</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Female gender (%)</td><td align="left" colspan="1" rowspan="1">50 (11/22)</td><td align="left" colspan="1" rowspan="1">47 (35/74)</td><td align="left" colspan="1" rowspan="1">47 (18/38)</td><td align="left" colspan="1" rowspan="1">45 (11/24)</td><td align="left" colspan="1" rowspan="1">56 (12/24)</td></tr><tr><td align="left" colspan="1" rowspan="1">Duration of diabetes (years)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">2&#8201;&#177;&#8201;2.5</td><td align="left" colspan="1" rowspan="1">6&#8201;&#177;&#8201;3.7<sup>&#8225;</sup></td><td align="left" colspan="1" rowspan="1">9&#8201;&#177;&#8201;5.0 <sup>&#8225; &#9674;</sup></td><td align="left" colspan="1" rowspan="1">9&#8201;&#177;&#8201;4.8 <sup>&#8225; &#9674;</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Oral hypoglycemic drugs (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">77 (57/74)</td><td align="left" colspan="1" rowspan="1">52 (20/38)<sup>&#8225;#</sup></td><td align="left" colspan="1" rowspan="1">58 (14/24)<sup>&#8225; #</sup></td><td align="left" colspan="1" rowspan="1">41 (10/24) <sup>&#8225;</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Insulin treatment (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">25 (19/74)</td><td align="left" colspan="1" rowspan="1">55 (21/38)<sup>&#8225;</sup></td><td align="left" colspan="1" rowspan="1">54 (13/24)<sup>&#8225;</sup></td><td align="left" colspan="1" rowspan="1">67 (16/24)<sup>&#8225; #</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Body mass index (kg/m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">22.0&#8201;&#177;&#8201;2.3</td><td align="left" colspan="1" rowspan="1">23.6&#8201;&#177;&#8201;2.3</td><td align="left" colspan="1" rowspan="1">24.3&#8201;&#177;&#8201;2.1</td><td align="left" colspan="1" rowspan="1">23.8&#8201;&#177;&#8201;2.3</td><td align="left" colspan="1" rowspan="1">24.4&#8201;&#177;&#8201;2.3</td></tr><tr><td align="left" colspan="1" rowspan="1">Systolic pressure (mmHg)</td><td align="left" colspan="1" rowspan="1">132&#8201;&#177;&#8201;21.4</td><td align="left" colspan="1" rowspan="1">133&#8201;&#177;&#8201;21.3</td><td align="left" colspan="1" rowspan="1">137&#8201;&#177;&#8201;21.4</td><td align="left" colspan="1" rowspan="1">144&#8201;&#177;&#8201;21.9</td><td align="left" colspan="1" rowspan="1">140&#8201;&#177;&#8201;20.3</td></tr><tr><td align="left" colspan="1" rowspan="1">Diastolic pressure (mmHg)</td><td align="left" colspan="1" rowspan="1">73&#8201;&#177;&#8201;13.8</td><td align="left" colspan="1" rowspan="1">81&#8201;&#177;&#8201;13.7 <sup>*</sup></td><td align="left" colspan="1" rowspan="1">78&#8201;&#177;&#8201;11.7 <sup>*</sup></td><td align="left" colspan="1" rowspan="1">79&#8201;&#177;&#8201;10.9 <sup>*</sup></td><td align="left" colspan="1" rowspan="1">77&#8201;&#177;&#8201;12.4 <sup>*</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Fasting glucose (mmol/l)</td><td align="left" colspan="1" rowspan="1">4.9&#8201;&#177;&#8201;0.63</td><td align="left" colspan="1" rowspan="1">9.1&#8201;&#177;&#8201;3.72<sup>*</sup></td><td align="left" colspan="1" rowspan="1">9.8&#8201;&#177;&#8201;3.13 <sup>*</sup></td><td align="left" colspan="1" rowspan="1">10.9&#8201;&#177;&#8201;3.71 <sup>*</sup></td><td align="left" colspan="1" rowspan="1">9.4&#8201;&#177;&#8201;3.59<sup>*</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">HbA1c (%)</td><td align="left" colspan="1" rowspan="1">5.4&#8201;&#177;&#8201;0.48</td><td align="left" colspan="1" rowspan="1">9.5&#8201;&#177;&#8201;2.52 <sup>*</sup></td><td align="left" colspan="1" rowspan="1">10.8&#8201;&#177;&#8201;3.09 <sup>*</sup></td><td align="left" colspan="1" rowspan="1">9.9&#8201;&#177;&#8201;2.25 <sup>*</sup></td><td align="left" colspan="1" rowspan="1">10.1&#8201;&#177;&#8201;2.59 <sup>*</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Cystatin C (mg/L)</td><td align="left" colspan="1" rowspan="1">0.97&#8201;&#177;&#8201;0.16</td><td align="left" colspan="1" rowspan="1">1.09&#8201;&#177;&#8201;0.29</td><td align="left" colspan="1" rowspan="1">0.99&#8201;&#177;&#8201;0.13</td><td align="left" colspan="1" rowspan="1">1.04&#8201;&#177;&#8201;0.20</td><td align="left" colspan="1" rowspan="1">1.50&#8201;&#177;&#8201;0.59 <sup>&#9651;</sup></td></tr></tbody></table><table-wrap-foot><p>Categorical variables expressed as frequencies were analyzed using a Chi-squared (&#967; 2) test. Data presented as mean (&#177;&#8201;SD) values were used ANOVA and t-test</p><p><sup>*</sup> compared to HC, <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.050; <sup>&#8225;</sup> compared to absent, <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.050; <sup>&#9674;</sup> compared to mild, <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.050; <sup>#</sup> compared to severe, <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.050; <sup>&#9651;</sup> compared to HC, absent, mild, and moderate, <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.050; HbA1c: glycated hemoglobin</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec10"><title>Lipid profile in DSPN patients</title><p id="Par35">In patients with moderate DSPN, a positive increase was found among TC, LDL-C, and APOB concentration (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) when compared to HC and DSPN with absent, mild and severe patients. Whereas, there were no significant differences in the concentrations of triglycerides, HDL-C, and APO-A1 between all the groups. In addition, diabetic patients had lower ratio of APO-A1/APOB than HC (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) (Table <xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Lipid profile of non-diabetic healthy controls (HC) and diabetic subjects with absent, mild, moderate and severe DSPN</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">HC</th><th align="left" colspan="1" rowspan="1">Absent</th><th align="left" colspan="1" rowspan="1">Mild</th><th align="left" colspan="1" rowspan="1">Moderate</th><th align="left" colspan="1" rowspan="1">Severe</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;22</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;74</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;38</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N = 24</italic></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N = 24</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">Total cholesterol (mmol/L)</td><td align="left" colspan="1" rowspan="1">4.08&#8201;&#177;&#8201;10.5</td><td align="left" colspan="1" rowspan="1">4.51&#8201;&#177;&#8201;1.40</td><td align="left" colspan="1" rowspan="1">4.67&#8201;&#177;&#8201;1.17</td><td align="left" colspan="1" rowspan="1">5.02 &#177;1.26<sup>*</sup></td><td align="left" colspan="1" rowspan="1">4.67 &#177;1.35</td></tr><tr><td align="left" colspan="1" rowspan="1">Triglycerides (mmol/L)</td><td align="left" colspan="1" rowspan="1">1.11&#8201;&#177;&#8201;0.62</td><td align="left" colspan="1" rowspan="1">2.18&#8201;&#177;&#8201;1.55</td><td align="left" colspan="1" rowspan="1">1.85&#8201;&#177;&#8201;1.27</td><td align="left" colspan="1" rowspan="1">1.83 &#177;1.76</td><td align="left" colspan="1" rowspan="1">1.97 &#177;1.51</td></tr><tr><td align="left" colspan="1" rowspan="1">HDL- Cholesterol (mmol/L)</td><td align="left" colspan="1" rowspan="1">1.29&#8201;&#177;&#8201;0.33</td><td align="left" colspan="1" rowspan="1">1.19&#8201;&#177;&#8201;0.36</td><td align="left" colspan="1" rowspan="1">1.15&#8201;&#177;&#8201;0.34</td><td align="left" colspan="1" rowspan="1">1.20 &#177;0.48</td><td align="left" colspan="1" rowspan="1">1.03 &#177;0.24</td></tr><tr><td align="left" colspan="1" rowspan="1">LDL- Cholesterol (mmol/L)</td><td align="left" colspan="1" rowspan="1">2.42&#8201;&#177;&#8201;0.92</td><td align="left" colspan="1" rowspan="1">2.64&#8201;&#177;&#8201;1.08</td><td align="left" colspan="1" rowspan="1">2.79&#8201;&#177;&#8201;0.85</td><td align="left" colspan="1" rowspan="1">3.15 &#177;1.01<sup>*</sup></td><td align="left" colspan="1" rowspan="1">2.93 &#177;0.97</td></tr><tr><td align="left" colspan="1" rowspan="1">APO-A1 (g/L)</td><td align="left" colspan="1" rowspan="1">1.35&#8201;&#177;&#8201;0.25</td><td align="left" colspan="1" rowspan="1">1.33&#8201;&#177;&#8201;0.27</td><td align="left" colspan="1" rowspan="1">1.28&#8201;&#177;&#8201;0.29</td><td align="left" colspan="1" rowspan="1">1.35 &#177;0.46</td><td align="left" colspan="1" rowspan="1">1.18 &#177;0.27</td></tr><tr><td align="left" colspan="1" rowspan="1">APOB (g/L)</td><td align="left" colspan="1" rowspan="1">0.81&#8201;&#177;&#8201;0.26</td><td align="left" colspan="1" rowspan="1">0.98&#8201;&#177;&#8201;0.35</td><td align="left" colspan="1" rowspan="1">0.97&#8201;&#177;&#8201;0.26</td><td align="left" colspan="1" rowspan="1">1.15 &#177;0.30<sup>*</sup></td><td align="left" colspan="1" rowspan="1">0.97 &#177;0.24</td></tr><tr><td align="left" colspan="1" rowspan="1">APO-A1/APOB</td><td align="left" colspan="1" rowspan="1">1.92&#8201;&#177;&#8201;0.64</td><td align="left" colspan="1" rowspan="1">1.55&#8201;&#177;&#8201;0.79 <sup>*</sup></td><td align="left" colspan="1" rowspan="1">1.40&#8201;&#177;&#8201;0.47 <sup>*</sup></td><td align="left" colspan="1" rowspan="1">1.34 &#177;0.50<sup>*</sup></td><td align="left" colspan="1" rowspan="1">1.26 &#177;0.41<sup>*</sup></td></tr></tbody></table><table-wrap-foot><p>Data presented as mean (&#177;&#8201;SD) values were used ANOAV and t-test</p><p><italic toggle="yes">APO-A1</italic> apolipoprotein-a1, <italic toggle="yes">APOB</italic> apolipoprotein-b</p><p><sup>*</sup> compared to HC, p&#8201;&#8804;&#8201;0.050</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Inflammatory biomarkers and IGF-1 are altered in DSPN</title><p id="Par36">In this study, we set out to measure 13 inflammatory markers, but could only detect 8 of them in our study population. Five of them were not usable for analysis because &gt;&#8201;75% of data below detection range. Among 8 inflammatory markers, patients with severe DSPN showed higher circulating levels of IFN-&#947;, IL-1&#946;, IL-4, IL-6 when compared to HC and diabetic patients without and with mild and moderate DSPN (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05). No differences between the groups were seen for TNF-&#945;, IL-2, IL-10, and hs-CPR (Table <xref rid="Tab4" ref-type="table">4</xref>). As shown in Table <xref rid="Tab4" ref-type="table">4</xref>, IGF-1 levels were lower in patients with diabetes compared to HC. Moreover, patients with severe DSPN showed significantly lower levels of IGF-1 compared to patients without and with mild, moderate DSPN (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05).</p><p id="Par37">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Circulating levels of inflammatory biomarkers and IGF-1</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">HC</th><th align="left" colspan="1" rowspan="1">absent</th><th align="left" colspan="1" rowspan="1">mild</th><th align="left" colspan="1" rowspan="1">moderate</th><th align="left" colspan="1" rowspan="1">severe</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;22</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;74</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;38</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;24</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;24</td></tr><tr><td align="left" colspan="1" rowspan="1">TNF-&#945;(pg/ml)</td><td align="left" colspan="1" rowspan="1">1.29&#8201;&#177;&#8201;0.75</td><td align="left" colspan="1" rowspan="1">2.69&#8201;&#177;&#8201;2.24</td><td align="left" colspan="1" rowspan="1">1.74&#8201;&#177;&#8201;1.13</td><td align="left" colspan="1" rowspan="1">1.91&#8201;&#177;&#8201;1.56</td><td align="left" colspan="1" rowspan="1">2.37&#8201;&#177;&#8201;2.26</td></tr><tr><td align="left" colspan="1" rowspan="1">INF-&#947; (pg/ml)</td><td align="left" colspan="1" rowspan="1">4.03&#8201;&#177;&#8201;2.10</td><td align="left" colspan="1" rowspan="1">5.74&#8201;&#177;&#8201;2.30</td><td align="left" colspan="1" rowspan="1">8.27&#8201;&#177;&#8201;4.43</td><td align="left" colspan="1" rowspan="1">6.18&#8201;&#177;&#8201;3.34</td><td align="left" colspan="1" rowspan="1">24.45&#8201;&#177;&#8201;7.84 <sup>*</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">IL-1&#946;(pg/ml)</td><td align="left" colspan="1" rowspan="1">12.63&#8201;&#177;&#8201;7.79</td><td align="left" colspan="1" rowspan="1">12.99&#8201;&#177;&#8201;8.65</td><td align="left" colspan="1" rowspan="1">17.12&#8201;&#177;&#8201;11.84</td><td align="left" colspan="1" rowspan="1">16.92&#8201;&#177;&#8201;11.72</td><td align="left" colspan="1" rowspan="1">60.33&#8201;&#177;&#8201;10.52 <sup>*</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">IL-2 (pg/ml)</td><td align="left" colspan="1" rowspan="1">1.71&#8201;&#177;&#8201;0.96</td><td align="left" colspan="1" rowspan="1">3.05&#8201;&#177;&#8201;2.64</td><td align="left" colspan="1" rowspan="1">2.58&#8201;&#177;&#8201;1.78</td><td align="left" colspan="1" rowspan="1">1.84&#8201;&#177;&#8201;1.02</td><td align="left" colspan="1" rowspan="1">3.25&#8201;&#177;&#8201;2.63</td></tr><tr><td align="left" colspan="1" rowspan="1">IL-4 (pg/ml)</td><td align="left" colspan="1" rowspan="1">1.13&#8201;&#177;&#8201;0.32</td><td align="left" colspan="1" rowspan="1">1.73&#8201;&#177;&#8201;1.05</td><td align="left" colspan="1" rowspan="1">1.73&#8201;&#177;&#8201;1.05</td><td align="left" colspan="1" rowspan="1">1.29&#8201;&#177;&#8201;0.68</td><td align="left" colspan="1" rowspan="1">3.68&#8201;&#177;&#8201;2.80 <sup>*</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">IL-6 (pg/ml)</td><td align="left" colspan="1" rowspan="1">2.51&#8201;&#177;&#8201;1.96</td><td align="left" colspan="1" rowspan="1">6.12&#8201;&#177;&#8201;4.13</td><td align="left" colspan="1" rowspan="1">4.78&#8201;&#177;&#8201;3.74</td><td align="left" colspan="1" rowspan="1">6.00&#8201;&#177;&#8201;5.34</td><td align="left" colspan="1" rowspan="1">25.66&#8201;&#177;&#8201;7.92 <sup>*</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">IL-10 (pg/ml)</td><td align="left" colspan="1" rowspan="1">2.36&#8201;&#177;&#8201;1.40</td><td align="left" colspan="1" rowspan="1">2.35&#8201;&#177;&#8201;1.14</td><td align="left" colspan="1" rowspan="1">3.31&#8201;&#177;&#8201;2.47</td><td align="left" colspan="1" rowspan="1">2.01&#8201;&#177;&#8201;1.89</td><td align="left" colspan="1" rowspan="1">4.25&#8201;&#177;&#8201;2.98</td></tr><tr><td align="left" colspan="1" rowspan="1">hs-CRP (mg/L)</td><td align="left" colspan="1" rowspan="1">1.91&#8201;&#177;&#8201;1.48</td><td align="left" colspan="1" rowspan="1">2.57&#8201;&#177;&#8201;1.81</td><td align="left" colspan="1" rowspan="1">2.01&#8201;&#177;&#8201;1.57</td><td align="left" colspan="1" rowspan="1">3.03&#8201;&#177;&#8201;2.24</td><td align="left" colspan="1" rowspan="1">2.60&#8201;&#177;&#8201;1.90</td></tr><tr><td align="left" colspan="1" rowspan="1">IGF-1 (ng/ml)</td><td align="left" colspan="1" rowspan="1">153.8&#8201;&#177;&#8201;22.33</td><td align="left" colspan="1" rowspan="1">117.12&#8201;&#177;&#8201;28.66 <sup>*</sup></td><td align="left" colspan="1" rowspan="1">78.83&#8201;&#177;&#8201;21.02 <sup>*</sup></td><td align="left" colspan="1" rowspan="1">62.22&#8201;&#177;&#8201;21.05 <sup>*</sup></td><td align="left" colspan="1" rowspan="1">52.22&#8201;&#177;&#8201;32.49 <sup>* &#8225;</sup></td></tr></tbody></table><table-wrap-foot><p>Data presented as mean (&#177;&#8201;SD) values were used ANOVA and t-test</p><p>
<italic toggle="yes">TNF-&#945; </italic>tumor necrosis factor- &#945;, <italic toggle="yes">INF-&#947;</italic> interferon-&#947;, <italic toggle="yes">IL</italic> interleukin, <italic toggle="yes">hs-CRP</italic> high- sensitivity C-reactive protein, <italic toggle="yes">IGF-1</italic> insulin- like growth factor-1</p><p><sup>*</sup> compared to absent, <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.050; <sup>&#8225;</sup> compared to HC, absent, mild and moderate, <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.050</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec12"><title>Multivariate ordered logistic regression analysis</title><p id="Par38">Variables showing significance were obtained odds ratio by analyzing multivariate ordered logistic regression to assess association between DSPN severity, demographic and clinic characteristic, lipids, inflammatory biomarkers. As shown in the Table <xref rid="Tab5" ref-type="table">5.</xref>, the levels of IL-1&#946; (OR&#8201;=&#8201;1.148, 95%CI 1.070&#8211;2.232; <italic toggle="yes">p</italic>&#8201;=&#8201;0.000), IL-6 (OR&#8201;=&#8201;3.166, 95%CI 1.461&#8211;6.860, <italic toggle="yes">p</italic>&#8201;=&#8201;0.003), TC (OR&#8201;=&#8201;1.174, 95%CI 1.011&#8211;1.364; <italic toggle="yes">p</italic>&#8201;=&#8201;0.035), LDL-C (OR&#8201;=&#8201;1.246, 95%CI 1.098&#8211;3.618; <italic toggle="yes">p</italic>&#8201;=&#8201;0.003), CysC (OR&#8201;=&#8201;1.867, 95%CI 1.245&#8211;3.434; <italic toggle="yes">p</italic>&#8201;=&#8201;0.004), ages (OR&#8201;=&#8201;1.043, 95%CI 1.009&#8211;1.078; <italic toggle="yes">p</italic>&#8201;=&#8201;0.012), and duration of diabetes (OR&#8201;=&#8201;1.157, 95%CI 1.049&#8211;1.277; <italic toggle="yes">p</italic>&#8201;=&#8201;0.004) were were positively associated with increasing the odds ration of DSPN in T2DM (Table <xref rid="Tab5" ref-type="table">5.</xref>). Conversely, the level of IGF-1 (OR&#8201;=&#8201;0.922, 95%CI 0.961&#8211;0.982; <italic toggle="yes">p</italic>&#8201;=&#8201;0.000) and ratio of APO-A1/APOB (OR&#8201;=&#8201;0.212, 95%CI 0.078&#8211;0.567; <italic toggle="yes">p</italic>&#8201;=&#8201;0.002) were significantly associated with decreasing the odds ratio of DSPN in T2DM (Table <xref rid="Tab5" ref-type="table">5.</xref>). There was no association between INF-&#947;, IL-4, fasting glucose, HbA1c, APOB and DSPN in T2DM. The &#8722;&#8201;2 log likelihood value of the whole model is 270.146, <italic toggle="yes">&#967; 2</italic>=&#8201;257.251, df&#8201;=&#8201;16, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, indicating <italic toggle="yes">the</italic> overall model is statistically significant.<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5.</label><caption><p>Multivariate ordinal logistic regression analysis </p></caption><graphic position="anchor" id="MO2" orientation="portrait" xlink:href="12883_2025_4379_Tab5_HTML.jpg"/><table-wrap-foot><p>a. Set to zero because this parameter is redundant; b. Fixed at the displayed value</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec13"><title>Discussion</title><p id="Par39">In this study, we found that increased inflammatory biomarkers such as IFN-&#947;, IL-1&#946;, IL-4, IL- 6 in patients with severe DSPN in T2DM. Patients with severe DSPN had lower level of IGF-1 and were higher level of CysC. Patients with moderate DSPN had higher TC, LDL-C, and APOB. Whereas, diabetic patients had lower ratio of APO-A1/APOB compared to HC. Moreover, patients with moderate and severe DSPN were a little older and had longer duration of diabetes compared to patients with absent and mild DSPN. No differences between the groups were seen for BMI, TNF-&#945;, IL-2, IL-10, and hs-CPR. Multivariate ordered logistic regression analysis showed that the levels of IL- 6, IL-1&#946;, TC, LDL-C, CysC, ages and duration of diabetes were were positively associated with DSPN in T2DM. Conversely, the level of IGF-1 and the ratio of APOA1/APOB were independent protective factors for DSPN in T2DM.</p><p id="Par40">Inflammatory biomarkers produced by immune and pancreatic islet cells are known to play diverse roles in diabetes. T helper cells (Th) are divided into two subgroups, Th1 and Th2 which regulate and suppress each other by mediating cytokines secretion [<xref ref-type="bibr" rid="CR17">17</xref>]. Th1 cells mainly secrete pro-inflammatory biomarkers such as TNF-&#945;, IFN-&#947;, IL-2, and IL-1&#946;, and Th2 cells mainly secrete anti-inflammatory IL-10, as well as IL-4, IL-5, and IL-6. However, the activation of the inflammatory cascade with downstream signaling and cytokines release may have dual effects in diabetic neuropathy [<xref ref-type="bibr" rid="CR18">18</xref>]. CRP, IL-6 and TNF-&#945; were most reported association with diabetic polynueropathy and some neuropathic deficits. It was reported that serum concentrations of IL-1 receptor antagonist (IL-1RA) were positively associated with the presence of DSPN and higher MNSI scores in age- and sex-adjusted analyses, whereas IL-6, IL-18 and soluble intercellular adhesion molecule-1 (sICAM-1) were positively associated with only MNSI scores [<xref ref-type="bibr" rid="CR7">7</xref>]. Furthermore, elevated plasma C-reactive protein (CRP), IL-6, TNF-&#945;, IL-1RA and sICAM, and decreased adiponectin concentration were found association with incident DSPN [<xref ref-type="bibr" rid="CR8">8</xref>]. After adjustment for known DSPN risk factors, increased IL-6 and TNF-&#945; remained association with incident DSPN, whereas higher plasma soluble ICAM-1 and IL-1RA were associated with the progression of DSPN [<xref ref-type="bibr" rid="CR8">8</xref>]. The finding for IL-6 in our study not only corroborates the report from the KORA F4 and KORA F4/FF4 studies [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>] but also is in line with other cross-sectional studies investigating in DSPN [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Moreover, association between higher TNF-&#945; and DSPN had been reported in a small study [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], whereas no associations were found in Herder C., et al&#8217;s studies [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>] that the similar results were also seen in our study. We also found that high circulating level of IL-6 was associated with DSPN in T2DM. We could not document abnormality in hsCRP, IL-2 and IL-10 in our patients. From a mechanistic point of view, TNF-&#945; is a promoter of the inflammatory response worsening insulin resistance. TNF-&#945; activates the transcription factor nuclear factor &#8211;&#954;B and thereby induces IL-6 expression [<xref ref-type="bibr" rid="CR8">8</xref>]. CRP, the typical inflammatory biomarker, is an acute-phase protein that is produced in the liver, and its main inducer is IL-6. Previous research reported that antihypertensive (ACEs, Ca-antagnists) and statins therapies actually led to the reduction of TNF-&#945; and CRP [<xref ref-type="bibr" rid="CR20">20</xref>]. The reason of no abnormality regarding TNF-&#945; and CRP in the present study might be explained by the fact that most diabetic patients who were included in our study had antihypertensive (ACEs, Ca-antagnists) and statins therapies (data no shown). IL-10 is generally regarded as an anti-inflammatory cytokine with the ability to adapt the immune response. Previous small cross-sectional study showed that IL-6 and IL-10 were raised in some DSPN patients, and correlated with abnormalities in large nerve fibers [<xref ref-type="bibr" rid="CR21">21</xref>]. Increased IL-10 in the study was regarded as a compensatory mechanism. We did not establish any difference in IL-10 concentration between all the groups, presumably due to different research assay and designs of our study.</p><p id="Par41">In the present study, IL-2 levels in the diabetic patients were not different from HC. This result was inconsistent with the study which was found that the level of IL-2 significantly decreased in the patients with T2DM compared to non-diabetic controls [<xref ref-type="bibr" rid="CR22">22</xref>]. There is accumulative evidences indicating that deficiencies in IL-2 highlight correlation to the development of T1DM [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>].The mechanistic link between IL-2 and DSPN is much less clear. Recent study found higher gene expression of IL-2, IL-8 and TNF in patients with small fiber neuropathy compared to controls [<xref ref-type="bibr" rid="CR25">25</xref>]. Thus, the conflicting findings implicate that systemic level of IL-2 is not specific but may be of potential importance in the development of T2DM with DSPN in association with other cytokines.</p><p id="Par42">IL-1&#946; is a proinflammatory and neuropoietic cytokine, which previous studies reported that it contributed to the development of T2DM by impairing both &#946;-cell function and insulin sensitivity [<xref ref-type="bibr" rid="CR26">26</xref>]. IL-1&#946; levels are kept under strict regulation by IL-1 receptor antagonist (IL-1RA). In rat model of diabetic neuropathy, high levels of circulating IL-1&#946; may be associated with the risk of diabetic peripheral neuropathy and anti-IL-1 treatment may provide a potential strategy for the prevention of diabetic neuropathy [<xref ref-type="bibr" rid="CR27">27</xref>]. Previous studies reported that individuals with specific manifestations of DSPN have higher serum IL-1 RA levels [<xref ref-type="bibr" rid="CR7">7</xref>]. In addition, higher serum IL-1 RA levels were association with the progression of DSPN over 6.5 years in an older general population [<xref ref-type="bibr" rid="CR8">8</xref>]. In the present study, we also observed that serum IL-1&#946; levels were increased in the group of sever DSPN which was a little older and had longer duration of diabetes. Moreover, the level of IL-1&#946; was associated with DSPN in T2DM. However, Sher EK et al., found there was no statistically higher level of IL-1&#946; presented in long-duration diabetes mellitus patients compared to the control group [<xref ref-type="bibr" rid="CR28">28</xref>]. The diverse results between the studies may be due to differences in the study assay or design or differences in the duration of the disease between the patients. IL-1&#946; levels were also affected by age, BMI and many genetic, hormonal and environmental factors [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p id="Par43">In the present study, the high significant increase of INF-&#947; and IL-4 were observed in patients with severe DSPN in T2DM. However, multivariate ordered logistic regression analysis showed that the levels of INF-&#947; and IL-4 were not associated with DSPN in T2DM. INF-&#947; as a cytokine for proinflammatory can be associated with Th1 cells, whereas, IL-4, the prototypic Th2-related cytokine, is generally considered as anti-inflammatory cytokine [<xref ref-type="bibr" rid="CR17">17</xref>]. Previous studies reported that INF-&#947; but not IL-4 was elevated in T2DM patients [<xref ref-type="bibr" rid="CR30">30</xref>]. Sokolova RN et al., found that serum levels of IL-4 and IL-5 were significantly higher in patients with T2DM. Furthermore, serum levels of IL-4 and IL- 5 positively correlated with BMI as well as waist circumference [<xref ref-type="bibr" rid="CR31">31</xref>]. In fact, emerging evidence clearly showed an inverse relationship between Th1/Th2 cytokines and the development of T2DM complications. Nekoua MP., et al. indicated that medical therapies effecting on cytokines were involved in immunomodulation such as serum concentrations of INF-&#947; and IL-4 decreased in insulin-treated type 2 diabetic patients [<xref ref-type="bibr" rid="CR32">32</xref>]. In addition, it has been recently reported that rosuvastatin treatment increased the IL-4 whereas no change was observed in INF-&#947; in type 2 diabetic &#8211;hypercholesterolemic patients [<xref ref-type="bibr" rid="CR33">33</xref>]. The explanation of diverse results between the studies may be due to differences in study assay or design, differences in impaired glucose homeostasis, insulin resistance and medical treatment between the patients. There are few reports on the research of INF &#8211;&#947; and IL-4 in DSPN. However, recent study reported that INF-&#947; was significantly increased in other peripheral neuropathy [<xref ref-type="bibr" rid="CR34">34</xref>]. IL-4 gene intron 3 VNTR polymorphism was reported association with diabetic peripheral neuropathy [<xref ref-type="bibr" rid="CR35">35</xref>]. It remains to be clarified in future studies whether modulation of Th1/Th2 cytokines represent an underlying pathophysiological mechanism or an epiphenomenon.</p><p id="Par44">IGF-1 provides trophic support for neurons of both the peripheral and central nervous systems. STZ-treated mice develop hyperalgesia at the early stage followed by hypoalgesia in the presence of significantly decreased systemic IGF-1 levels [<xref ref-type="bibr" rid="CR9">9</xref>]. Early treatment with an IGF-1 plasmid increases serum IGF-1 without correcting hyperglycemia, but preventing later hypoalgesia and improving mobility in STZ &#8211;treated diabetic mice [<xref ref-type="bibr" rid="CR9">9</xref>]. Type 1 diabetic patients with neuropathy showed a more pronounced fall in serum free IGF-1 [<xref ref-type="bibr" rid="CR12">12</xref>]. Recently in a cross-sectional study, type 2 diabetic patients with peripheral neuropathy exhibited significantly lower levels of IGF-1 compared with non-diabetic peripheral neuropathy [<xref ref-type="bibr" rid="CR36">36</xref>]. Similar finding for IGF-1 was also observed in our study. We also found that the level of IGF-1 was an independent protective factor for DSPN in T2DM. The mechanisms how IGF-1 implement nerve growth and repair are not completely understood. In cultured DRG neurons from STZ-diabetic rats, IGF-1 activates and up-regulates AMPK to elevate mitochondrial function and drive axonal outgrowth [<xref ref-type="bibr" rid="CR37">37</xref>]. It is proposed that IGF-1 signals via AMPK mediate IGF-1 dependent protection from distal dying-back of fibers in diabetic neuropathy [<xref ref-type="bibr" rid="CR37">37</xref>]. Since high variability within individual is likely a challenge in investigating association between IGF-1 and long term outcomes, future study of IGF-1 in T2DM needs to establish its patterns with duration, age, gender, glycemic control, insulin level and other factors to track IGF-1 within individuals over time.</p><p id="Par45">The serum lipids profile associated with neuropathy in T2DM is not well understood. Numerous studies have provided evidence that dyslipidemia, obesity and additional components of the metabolic syndrome, such as hypertension, are important neuropathy risk factors [<xref ref-type="bibr" rid="CR38">38</xref>&#8211;<xref ref-type="bibr" rid="CR40">40</xref>]. In the Danish ADDITION T2DM cohort, peripheral neuropathy is associated with decreased HDL-C [<xref ref-type="bibr" rid="CR38">38</xref>]. Elevated triglycerides associated with peripheral neuropathy in the Danish Centre for Strategic Research in T2DM cohort [<xref ref-type="bibr" rid="CR40">40</xref>] and risk for nontraumatic lower-extremity amputations in the DISTANCE study [<xref ref-type="bibr" rid="CR40">40</xref>]. In addition, systolic and diastolic blood pressures were elevated in participants with versus without neuropathy [<xref ref-type="bibr" rid="CR41">41</xref>]. In the present study, we observed that patients with moderate DSPN had higher TC, LDL-C, and APOB. Diabetic patients with or without DSPN had significantly lower serum APO- A1-to-APOB ratio compared to HC. In addition, logistic regression analysis showed that TC and LDL-C were associated with DSPN in T2DM. Whereas the ratio of APO-A1/APOB was an independent protective factor for DSPN in T2DM. We also found only diastolic blood pressure elevated in diabetic patients with and without DSPN. Different results may be due to relatively smaller sample size and the intermediate and complex lipids, which may associate with future incident neuropathy. Besides, APO-A1, the main HDL structural protein that is produced by the liver and intestine, is essential for reverse transport of cholesterol from peripheral tissue to the liver. It also has antioxidant and anti-inflammatory effects [<xref ref-type="bibr" rid="CR42">42</xref>]. On the contrary, APOB is present in VLDL, intermediate-density lipoprotein (IDL), LDL, and lipoprotein (a) being responsible for delivering lipids from the liver and intestine to peripheral tissue. There is evidence demonstrated that low ration of APO-A1/APOB in serum was associated with proliferative diabetic retinopathy in T2DM [<xref ref-type="bibr" rid="CR43">43</xref>]. A nest case-control study conducted within an ongoing prospective study on patients with T2DM reported that serum APO-A1 but not HDL-C is straightly associated with diabetic neuropathy [<xref ref-type="bibr" rid="CR44">44</xref>]. But, Very few reports from the literature are available to compare the association between APO- A1/APOB ratio and T2DM with DSPN. We speculate that low concentrations of ApoA1-to- ApoB may have a protective effect on patients with DSPN. More studies are needed in future to elucidate the mechanisms for these associations.</p><p id="Par46">Previous study has indicated that reduced estimated glomerular filtration rate (eGFR) is the predictor of renal function impairment in patients with diabetic neuropathy [<xref ref-type="bibr" rid="CR45">45</xref>]. The gold standard in measured GFR utilizes the urinary plasma clearance of exogenous filtration markers such as inulin or iothalamate. However, this is not routinely performed because of the complexity of measurement. Serum CysC is a sensitive marker of kidney function and the use of CysC as a confirmatory test in patients with an uncertain diagnosis of chronic kidney disease may be beneficial [<xref ref-type="bibr" rid="CR46">46</xref>]. In a cross-sectional study of a Chinese type 2 diabetic population, high serum CysC level is closely associated with diabetic peripheral neuropathy [<xref ref-type="bibr" rid="CR47">47</xref>]. The study suggested that high serum CysC level may be a potential biomarker for diabetic peripheral neuropathy in T2DM [<xref ref-type="bibr" rid="CR46">46</xref>]. In the present study, we also found that high serum CysC level was significantly increased in the patients with severe DSPN compared to HC and patients with absent, mild and moderate DSPN. In addition, multivariate ordered logistic regression analysis showed that CysC level was associated with DSPN in T2DM. We suggest that early detection of CysC level and the therapeutic strategy for diabetes should provide early management of impaired renal function.</p><p id="Par47">This study also has limitations. First, this study is cross-sectional design, which it is not useful to assume the causality between inflammatory biomarkers and the development of DSPN. Second, our definition of DSPN only diagnosed criteria for probable DSPN, not for confirmed DSPN. Third, our study relied on measurements of inflammatory biomarkers and biochemical parameters at a single time point only, and an individual metabolic status can vary in diabetes with DSPN. Hence, a single measurement may not accurately reflect long-term levels. Finally, our study group is a little small as we confirmed by post-hoc sample size calculation, if a larger sample size were calculated specifically to this study, it would have provided greater statistical power. But we believe that our analysis are useful exploratory. Further research on larger cohorts is needed.</p></sec><sec id="Sec14"><title>Conclusions</title><p id="Par48">The levels of inflammatory biomarkers such as INF-&#947;, IL-1&#946;, IL-4, IL- 6 were increased in patients with severe DSPN in T2DM. Ages, duration of diabetes as well as high circulating levels of IL-6, IL-1&#946;, TC, LDL-C and Cystatin C were positively associated with DSPN in T2DM. Conversely, the level of IGF-1 and the ratio of APOA1/APOB were independent protective factors for DSPN in T2DM. Our results emphasize the importance of addressing issues related to inflammatory biomarkers, lipids and early impaired renal function in T2DM with DSPN, as these may be of potential relevance for deteriorating DSPN.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>DSPN</term><def><p id="Par5">Diabetic distal sensorimotor polyneuropathy</p></def></def-item><def-item><term>BMI</term><def><p id="Par6">Body mass index</p></def></def-item><def-item><term>T2DM</term><def><p id="Par7">Type 2 diabetes mellitus</p></def></def-item><def-item><term>HbA1c</term><def><p id="Par8">Glycated hemoglobin</p></def></def-item><def-item><term>CysC</term><def><p id="Par9">Cystatin C</p></def></def-item><def-item><term>TC</term><def><p id="Par10">Total cholesterol</p></def></def-item><def-item><term>TG</term><def><p id="Par11">Triglycerides</p></def></def-item><def-item><term>HDL-C</term><def><p id="Par12">High density lipoprotein cholesterol</p></def></def-item><def-item><term>LDL-C</term><def><p id="Par13">Low density lipoprotein cholesterol</p></def></def-item><def-item><term>APO-A1</term><def><p id="Par14">Apolipoprotein-a1</p></def></def-item><def-item><term>APOB</term><def><p id="Par15">apolipoprotein-b</p></def></def-item><def-item><term>TNF-&#945;</term><def><p id="Par16">tumor necrosis factor-&#945;</p></def></def-item><def-item><term>INF-&#947;</term><def><p id="Par17">interferon-&#947;</p></def></def-item><def-item><term>IL</term><def><p id="Par18">interleukin</p></def></def-item><def-item><term>hs-CRP</term><def><p id="Par19">high-sensitivity C-reactive protein</p></def></def-item><def-item><term>IGF-1</term><def><p id="Par20">insulin-like growth factor-1</p></def></def-item><def-item><term>MNSI</term><def><p id="Par21">Michigan Neuropathy Screening Instrument</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We are grateful to Jinliao Tang for assistance in bold sample collection, and to Xiaorong Wei for helping with measuring inflammatory markers.</p></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>S H contributed to conduction of the study, data analysis and interpretation and critical revision of the manuscript. C Z, Y L and H L performed the nerve tests, participated in data collected, and in the discussion and writing the manuscript. Y W participated in data analysis and interpretation, as well as manuscript writing. BC designed and supervised the study, interpreted the data, participated in writing the manuscript and was responsible for funding acquisition. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Dr. BC was supported by a research grant from scientific research and technology development plan project in Wuming district, Nanning city, Guangxi, China (WM-20190404).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data used to support the findings of this study are available from the corresponding author upon request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par49">This study involves human participants and was approved by Wuming Hospital Ethics Committee (WM- 20190404). Participants gave informed consent to participate in the study before taking part written informed consent to participate was obtained from patients before their enlistment in the study.This study was performed in accordance with the Declaration of Helsinki.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par50">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par51">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heald</surname><given-names>AH</given-names></name><name name-style="western"><surname>Stedman</surname><given-names>M</given-names></name><name name-style="western"><surname>Davies</surname><given-names>M</given-names></name><name name-style="western"><surname>Livingston</surname><given-names>M</given-names></name><name name-style="western"><surname>Alshames</surname><given-names>R</given-names></name><name name-style="western"><surname>Lunt</surname><given-names>M</given-names></name><etal/></person-group><article-title>Estimating life years lost to diabetes: outcomes from analysis of National diabetes audit and office of National statistics data</article-title><source>Cardiovasc Endocrinal Metab</source><year>2020</year><volume>9</volume><fpage>183</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1097/XCE.0000000000000210</pub-id><pub-id pub-id-type="pmcid">PMC7673790</pub-id><pub-id pub-id-type="pmid">33225235</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Heald AH, Stedman M, Davies M, Livingston M, Alshames R, Lunt M, et al. Estimating life years lost to diabetes: outcomes from analysis of National diabetes audit and office of National statistics data. Cardiovasc Endocrinal Metab. 2020;9:183&#8211;5.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/XCE.0000000000000210</pub-id><pub-id pub-id-type="pmcid">PMC7673790</pub-id><pub-id pub-id-type="pmid">33225235</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>S</given-names></name><name name-style="western"><surname>Pouya</surname><given-names>S</given-names></name><name name-style="western"><surname>Suvi</surname><given-names>K</given-names></name><name name-style="western"><surname>Moritz</surname><given-names>P</given-names></name><name name-style="western"><surname>Katherine</surname><given-names>O</given-names></name><name name-style="western"><surname>Bruce</surname><given-names>B</given-names></name><etal/></person-group><article-title>IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045</article-title><source>Diabetes Res Clin Pract</source><year>2022</year><volume>183</volume><issue>109119</issue><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2021.109119</pub-id><pub-id pub-id-type="pmcid">PMC11057359</pub-id><pub-id pub-id-type="pmid">34879977</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Hong S, Pouya S, Suvi K, Moritz P, Katherine O, Bruce B, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183(109119):1&#8211;13.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2021.109119</pub-id><pub-id pub-id-type="pmcid">PMC11057359</pub-id><pub-id pub-id-type="pmid">34879977</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ziegler</surname><given-names>D</given-names></name><name name-style="western"><surname>Papanas</surname><given-names>N</given-names></name><name name-style="western"><surname>Vinik</surname><given-names>AI</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>JE</given-names></name></person-group><article-title>Epidemiology of polyneuropathy in diabetes and prediabetes</article-title><source>Handb Clin Neurol</source><year>2014</year><volume>126</volume><fpage>3</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/B978-0-444-53480-4.00001-1</pub-id><pub-id pub-id-type="pmid">25410210</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">3, Ziegler D, Papanas N, Vinik AI, Shaw JE. Epidemiology of polyneuropathy in diabetes and prediabetes. Handb Clin Neurol. 2014;126:3&#8211;22.<pub-id pub-id-type="pmid">25410210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/B978-0-444-53480-4.00001-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doupis</surname><given-names>J</given-names></name><name name-style="western"><surname>Lyous</surname><given-names>TE</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S</given-names></name><name name-style="western"><surname>Gnardellis</surname><given-names>C</given-names></name><name name-style="western"><surname>Dinh</surname><given-names>T</given-names></name><name name-style="western"><surname>Veves</surname><given-names>A</given-names></name></person-group><article-title>Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy</article-title><source>J Clin Endocrinol Metab</source><year>2009</year><volume>94</volume><issue>6</issue><fpage>2157</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1210/jc.2008-2385</pub-id><pub-id pub-id-type="pmid">19276232</pub-id><pub-id pub-id-type="pmcid">PMC2690431</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">4, Doupis J, Lyous TE, Wu S, Gnardellis C, Dinh T, Veves A. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J Clin Endocrinol Metab. 2009;94(6):2157&#8211;63.<pub-id pub-id-type="pmid">19276232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2008-2385</pub-id><pub-id pub-id-type="pmcid">PMC2690431</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duksal</surname><given-names>T</given-names></name><name name-style="western"><surname>Tiftikcioglu</surname><given-names>BI</given-names></name><name name-style="western"><surname>Bilgin</surname><given-names>S</given-names></name><name name-style="western"><surname>Kose</surname><given-names>S</given-names></name><name name-style="western"><surname>Zorlu</surname><given-names>Y</given-names></name></person-group><article-title>Role of inflammation in sensory neuropathy in prediabetes or diabetes</article-title><source>Acta Neurol Scand</source><year>2016</year><volume>133</volume><issue>5</issue><fpage>384</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1111/ane.12474</pub-id><pub-id pub-id-type="pmid">26346888</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">5, Duksal T, Tiftikcioglu BI, Bilgin S, Kose S, Zorlu Y. Role of inflammation in sensory neuropathy in prediabetes or diabetes. Acta Neurol Scand. 2016;133(5):384&#8211;90.<pub-id pub-id-type="pmid">26346888</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ane.12474</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herder</surname><given-names>C</given-names></name><name name-style="western"><surname>Lankisch</surname><given-names>M</given-names></name><name name-style="western"><surname>Ziegler</surname><given-names>D</given-names></name><name name-style="western"><surname>Rathman</surname><given-names>W</given-names></name><name name-style="western"><surname>Koening</surname><given-names>W</given-names></name><name name-style="western"><surname>Illig</surname><given-names>T</given-names></name><etal/></person-group><article-title>Subclinical inflammation and diabetic polyneuropathy: MONICA/KORA survey F3 (Augsburg, Germany)</article-title><source>Diabetes Care</source><year>2009</year><volume>32</volume><fpage>680</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.2337/dc08-2011</pub-id><pub-id pub-id-type="pmid">19131463</pub-id><pub-id pub-id-type="pmcid">PMC2660451</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">6, Herder C, Lankisch M, Ziegler D, Rathman W, Koening W, Illig T, et al. Subclinical inflammation and diabetic polyneuropathy: MONICA/KORA survey F3 (Augsburg, Germany). Diabetes Care. 2009;32:680&#8211;2.<pub-id pub-id-type="pmid">19131463</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc08-2011</pub-id><pub-id pub-id-type="pmcid">PMC2660451</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herder</surname><given-names>C</given-names></name><name name-style="western"><surname>Koenig</surname><given-names>W</given-names></name><name name-style="western"><surname>Bongaerts</surname><given-names>BWC</given-names></name><name name-style="western"><surname>Thorand</surname><given-names>B</given-names></name><name name-style="western"><surname>Rathmann</surname><given-names>W</given-names></name><name name-style="western"><surname>Kowall</surname><given-names>B</given-names></name><etal/></person-group><article-title>Association of subclinical inflammation with polyneuropathy in the older population KORA F4 study</article-title><source>Diabetes Care</source><year>2013</year><volume>36</volume><fpage>3663</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.2337/dc13-0382</pub-id><pub-id pub-id-type="pmid">24009302</pub-id><pub-id pub-id-type="pmcid">PMC3816905</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">7, Herder C, Koenig W, Bongaerts BWC, Thorand B, Rathmann W, Kowall B, et al. Association of subclinical inflammation with polyneuropathy in the older population KORA F4 study. Diabetes Care. 2013;36:3663&#8211;70.<pub-id pub-id-type="pmid">24009302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc13-0382</pub-id><pub-id pub-id-type="pmcid">PMC3816905</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herder</surname><given-names>C</given-names></name><name name-style="western"><surname>Kannenberg</surname><given-names>JM</given-names></name><name name-style="western"><surname>Huth</surname><given-names>C</given-names></name><name name-style="western"><surname>Carstensen-Kirberg</surname><given-names>M</given-names></name><name name-style="western"><surname>Rathmann</surname><given-names>W</given-names></name><name name-style="western"><surname>Koenig</surname><given-names>W</given-names></name><etal/></person-group><article-title>Proinflammatory cytokines predict the incidence and progression of distal sensorimotor polyneuropathy: KORA F4/FF4 study</article-title><source>Diabetes Care</source><year>2017</year><volume>40</volume><fpage>569</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.2337/dc16-2259</pub-id><pub-id pub-id-type="pmid">28174259</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">8, Herder C, Kannenberg JM, Huth C, Carstensen-Kirberg M, Rathmann W, Koenig W, et al. Proinflammatory cytokines predict the incidence and progression of distal sensorimotor polyneuropathy: KORA F4/FF4 study. Diabetes Care. 2017;40:569&#8211;76.<pub-id pub-id-type="pmid">28174259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc16-2259</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Moreland</surname><given-names>R</given-names></name><name name-style="western"><surname>Yew</surname><given-names>NS</given-names></name><name name-style="western"><surname>Foley</surname><given-names>J</given-names></name><name name-style="western"><surname>Ziegler</surname><given-names>R</given-names></name><name name-style="western"><surname>Scheule</surname><given-names>RK</given-names></name></person-group><article-title>Systemic insulin-like factor-1 reverses hypoalgesia and improves mobility in a mouse model of diabetic peripheral neuropathy</article-title><source>Am Soc Gene Therapy</source><year>2008</year><volume>16</volume><issue>8</issue><fpage>1400</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/mt.2008.115</pub-id><pub-id pub-id-type="pmid">18545223</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">9, Chu Q, Moreland R, Yew NS, Foley J, Ziegler R, Scheule RK. Systemic insulin-like factor-1 reverses hypoalgesia and improves mobility in a mouse model of diabetic peripheral neuropathy. Am Soc Gene Therapy. 2008;16(8):1400&#8211;8.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mt.2008.115</pub-id><pub-id pub-id-type="pmid">18545223</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>G</given-names></name><name name-style="western"><surname>Sima</surname><given-names>AAF</given-names></name></person-group><article-title>Altered immediate early gene expression in injured diabetic nerve: implications in regeneration</article-title><source>J Neuropathol Exp Neurol</source><year>2001</year><volume>60</volume><fpage>972</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1093/jnen/60.10.972</pub-id><pub-id pub-id-type="pmid">11589428</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">10, Xu G, Sima AAF. Altered immediate early gene expression in injured diabetic nerve: implications in regeneration. J Neuropathol Exp Neurol. 2001;60:972&#8211;83.<pub-id pub-id-type="pmid">11589428</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnen/60.10.972</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pierson</surname><given-names>CR</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Murakawa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sima</surname><given-names>AAF</given-names></name></person-group><article-title>Early gene responses of trophic factors in nerve regeneration differ in experimental type 1 and type 2 diabetic polyneuropathies</article-title><source>J Neuropathol Exp Neurol</source><year>2002</year><volume>61</volume><issue>10</issue><fpage>857</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1093/jnen/61.10.857</pub-id><pub-id pub-id-type="pmid">12387452</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">11, Pierson CR, Zhang W, Murakawa Y, Sima AAF. Early gene responses of trophic factors in nerve regeneration differ in experimental type 1 and type 2 diabetic polyneuropathies. J Neuropathol Exp Neurol. 2002;61(10):857&#8211;71.<pub-id pub-id-type="pmid">12387452</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnen/61.10.857</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Capoluongo</surname><given-names>E</given-names></name><name name-style="western"><surname>Pitocco</surname><given-names>D</given-names></name><name name-style="western"><surname>Santonocito</surname><given-names>C</given-names></name><name name-style="western"><surname>Concolino</surname><given-names>P</given-names></name><name name-style="western"><surname>Santini</surname><given-names>SA</given-names></name><name name-style="western"><surname>Manto</surname><given-names>A</given-names></name><etal/></person-group><article-title>Association between serum free IGF-1 and IGFBP-3 levels in type-1 diabetes patients affected with associated autoimmune diseases or diabetic complications</article-title><source>Eur Cytokine Netw</source><year>2006</year><volume>17</volume><issue>3</issue><fpage>167</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">17194636</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">12, Capoluongo E, Pitocco D, Santonocito C, Concolino P, Santini SA, Manto A, et al. Association between serum free IGF-1 and IGFBP-3 levels in type-1 diabetes patients affected with associated autoimmune diseases or diabetic complications. Eur Cytokine Netw. 2006;17(3):167&#8211;74.<pub-id pub-id-type="pmid">17194636</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Supplement-1):S81&#8211;90.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc14-S081</pub-id><pub-id pub-id-type="pmid">24357215</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feldman</surname><given-names>EL</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>PK</given-names></name><name name-style="western"><surname>Brown</surname><given-names>MB</given-names></name><name name-style="western"><surname>Canal</surname><given-names>N</given-names></name><name name-style="western"><surname>Greene</surname><given-names>DA</given-names></name></person-group><article-title>A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy</article-title><source>Diabetes Care</source><year>1994</year><volume>17</volume><fpage>1281</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.2337/diacare.17.11.1281</pub-id><pub-id pub-id-type="pmid">7821168</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">14, Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17:1281&#8211;9.<pub-id pub-id-type="pmid">7821168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/diacare.17.11.1281</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sher</surname><given-names>EK</given-names></name><name name-style="western"><surname>Prnjavorac</surname><given-names>B</given-names></name><name name-style="western"><surname>Farhat</surname><given-names>EK</given-names></name><name name-style="western"><surname>Palic</surname><given-names>B</given-names></name><name name-style="western"><surname>Ansar</surname><given-names>S</given-names></name><name name-style="western"><surname>Sher</surname><given-names>F</given-names></name></person-group><article-title>Effect of diabetic neuropathy on reparative ability and immune response system</article-title><source>Mol Biotchnoloby</source><year>2023</year><pub-id pub-id-type="doi">10.1007/s12033-023-00813-z</pub-id><pub-id pub-id-type="pmid">37523019</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">15, Sher EK, Prnjavorac B, Farhat EK, Palic B, Ansar S, Sher F. Effect of diabetic neuropathy on reparative ability and immune response system. Mol Biotchnoloby. 2023. 10.1007/s12033-023-00813-z.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12033-023-00813-z</pub-id><pub-id pub-id-type="pmid">37523019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haque</surname><given-names>F</given-names></name><name name-style="western"><surname>Reaz</surname><given-names>MBI</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>MEH</given-names></name><name name-style="western"><surname>Shapiai</surname><given-names>MIB</given-names></name><name name-style="western"><surname>Malik</surname><given-names>RA</given-names></name><name name-style="western"><surname>Alhatou</surname><given-names>M</given-names></name><etal/></person-group><article-title>A machine learning-based severity prediction tool for the Michigan neuropathy screening instrument</article-title><source>Diagnostics</source><year>2023</year><volume>13</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.3390/diagnostics13020264</pub-id><pub-id pub-id-type="pmcid">PMC9857736</pub-id><pub-id pub-id-type="pmid">36673074</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">16, Haque F, Reaz MBI, Chowdhury MEH, Shapiai MIB, Malik RA, Alhatou M, et al. A machine learning-based severity prediction tool for the Michigan neuropathy screening instrument. Diagnostics. 2023;13:264: 1&#8211;16.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/diagnostics13020264</pub-id><pub-id pub-id-type="pmcid">PMC9857736</pub-id><pub-id pub-id-type="pmid">36673074</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vargas-Rojas</surname><given-names>MI</given-names></name><name name-style="western"><surname>Solleiro-Villavicencio</surname><given-names>H</given-names></name><name name-style="western"><surname>Soto-Vega</surname><given-names>E</given-names></name></person-group><article-title>Th1, Th2, Th17 and Treg levels in umbilical cord blood in preeclampsia</article-title><source>J Matern Fetal Neonatal Med</source><year>2015</year><volume>29</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/14767058.2015.1057811</pub-id><pub-id pub-id-type="pmid">26135758</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">., 17, Vargas-Rojas MI, Solleiro-Villavicencio H, Soto-Vega E. Th1, Th2, Th17 and Treg levels in umbilical cord blood in preeclampsia. J Matern Fetal Neonatal Med 2015; 29: 1&#8211;14.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/14767058.2015.1057811</pub-id><pub-id pub-id-type="pmid">26135758</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pop-Busui</surname><given-names>R</given-names></name><name name-style="western"><surname>Ang</surname><given-names>L</given-names></name><name name-style="western"><surname>Hilmes</surname><given-names>C</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>K</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>EL</given-names></name></person-group><article-title>Inflammation as a therapeutic target for diabetic neuropathies</article-title><source>Curr Dia Rep</source><year>2016</year><volume>16</volume><issue>3</issue><fpage>29doi</fpage><pub-id pub-id-type="doi">10.1007/s1189-016-0727-5</pub-id><pub-id pub-id-type="pmcid">PMC5127166</pub-id><pub-id pub-id-type="pmid">26897744</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">18, Pop-Busui R, Ang L, Hilmes C, Gallagher K, Feldman EL. Inflammation as a therapeutic target for diabetic neuropathies. Curr Dia Rep. 2016;16(3):29doi. 10.1007/s1189-016-0727-5.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11892-016-0727-5</pub-id><pub-id pub-id-type="pmcid">PMC5127166</pub-id><pub-id pub-id-type="pmid">26897744</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hussain</surname><given-names>G</given-names></name><name name-style="western"><surname>Rizvi</surname><given-names>SAA</given-names></name><name name-style="western"><surname>Singhal</surname><given-names>S</given-names></name><name name-style="western"><surname>Zubair</surname><given-names>M</given-names></name><name name-style="western"><surname>Ahamad</surname><given-names>J</given-names></name></person-group><article-title>Serum levels of TNF-&#945; in peripheral neuropathy patients and its correlation with nerve conduction velocity in type 2 diabetes mellitus</article-title><source>Diabetes Metab Syndr</source><year>2013</year><volume>7</volume><fpage>238</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.dsx.2013.02.005</pub-id><pub-id pub-id-type="pmid">24290092</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">AQ19, Hussain G, Rizvi SAA, Singhal S, Zubair M, Ahamad J. Serum levels of TNF-&#945; in peripheral neuropathy patients and its correlation with nerve conduction velocity in type 2 diabetes mellitus. Diabetes Metab Syndr. 2013;7:238&#8211;42.<pub-id pub-id-type="pmid">24290092</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dsx.2013.02.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Derosa</surname><given-names>G</given-names></name><name name-style="western"><surname>Mugellini</surname><given-names>A</given-names></name><name name-style="western"><surname>Pesce</surname><given-names>RM</given-names></name><name name-style="western"><surname>D&#8217;Angelo</surname><given-names>A</given-names></name><name name-style="western"><surname>Maffioli</surname><given-names>P</given-names></name></person-group><article-title>Perindopril and barnidipine alone or combined with Simvastatin on hepatic steatosis and inflammatory parameters in hypertensive patients</article-title><source>Eur J Pharmacol</source><year>2015</year><volume>766</volume><fpage>31</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2015.09.030</pub-id><pub-id pub-id-type="pmid">26407654</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">20, Derosa G, Mugellini A, Pesce RM, D&#8217;Angelo A, Maffioli P. Perindopril and barnidipine alone or combined with Simvastatin on hepatic steatosis and inflammatory parameters in hypertensive patients. Eur J Pharmacol. 2015;766:31&#8211;6.<pub-id pub-id-type="pmid">26407654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2015.09.030</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><collab>21</collab><name name-style="western"><surname>Marinelli</surname><given-names>F</given-names></name><name name-style="western"><surname>Briani</surname><given-names>C</given-names></name><name name-style="western"><surname>Romano</surname><given-names>M</given-names></name><name name-style="western"><surname>Ruggero</surname><given-names>S</given-names></name><name name-style="western"><surname>Toffanin</surname><given-names>E</given-names></name><name name-style="western"><surname>Triolo</surname><given-names>G</given-names></name><etal/></person-group><article-title>The association between serum cytokines and damage to large and small nerve fibers in diabetic peripheral neuropathy</article-title><source>J Diabetes Res</source><year>2015</year><volume>2015</volume><fpage>547834</fpage><pub-id pub-id-type="pmid">25961054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2015/547834</pub-id><pub-id pub-id-type="pmcid">PMC4415740</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">21, Marinelli F, Briani C, Romano M, Ruggero S, Toffanin E, Triolo G, et al. The association between serum cytokines and damage to large and small nerve fibers in diabetic peripheral neuropathy. J Diabetes Res. 2015;2015:547834.<pub-id pub-id-type="pmid">25961054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2015/547834</pub-id><pub-id pub-id-type="pmcid">PMC4415740</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suri</surname><given-names>S</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>P</given-names></name><name name-style="western"><surname>Abhilasha</surname><given-names>A</given-names></name><name name-style="western"><surname>Saxena</surname><given-names>I</given-names></name><name name-style="western"><surname>Garg</surname><given-names>MK</given-names></name><name name-style="western"><surname>Bohra</surname><given-names>GK</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>P</given-names></name></person-group><article-title>Role of interleukin-2 and interleukin-18 in newly diagnosed type 2 diabetes mellitus</article-title><source>J Basic Clin Physiol Pharmacol</source><year>2021</year><volume>15</volume><issue>33</issue><fpage>185</fpage><lpage>90</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/jbcpp-2020-0272</pub-id><pub-id pub-id-type="pmid">33711216</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">AQ22, Suri S, Mitra P, Abhilasha A, Saxena I, Garg MK, Bohra GK, Sharma P. Role of interleukin-2 and interleukin-18 in newly diagnosed type 2 diabetes mellitus. J Basic Clin Physiol Pharmacol. 2021;15(33):185&#8211;90.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/jbcpp-2020-0272</pub-id><pub-id pub-id-type="pmid">33711216</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><collab>23</collab><name name-style="western"><surname>Dogan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Akarsu</surname><given-names>S</given-names></name><name name-style="western"><surname>Ustundag</surname><given-names>B</given-names></name><name name-style="western"><surname>Yilmaz</surname><given-names>E</given-names></name><name name-style="western"><surname>Gurgoze</surname><given-names>MK</given-names></name></person-group><article-title>Serum IL-1&#946;, IL-2 and IL-6 in insulin-dependent diabetic children</article-title><source>Mediators Inflamm</source><year>2006</year><volume>2006</volume><issue>1</issue><fpage>59206</fpage><pub-id pub-id-type="doi">10.1155/MI/2006/59206</pub-id><pub-id pub-id-type="pmid">16864906</pub-id><pub-id pub-id-type="pmcid">PMC1570393</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">23, Dogan Y, Akarsu S, Ustundag B, Yilmaz E, Gurgoze MK. Serum IL-1&#946;, IL-2 and IL-6 in insulin-dependent diabetic children. Mediators Inflamm. 2006;2006(1):59206.<pub-id pub-id-type="pmid">16864906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/MI/2006/59206</pub-id><pub-id pub-id-type="pmcid">PMC1570393</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalil</surname><given-names>RG</given-names></name><name name-style="western"><surname>Abdel-Moneim</surname><given-names>A</given-names></name><name name-style="western"><surname>Yousef</surname><given-names>AI</given-names></name><name name-style="western"><surname>Abdel-Rahman</surname><given-names>H</given-names></name><name name-style="western"><surname>Zanaty</surname><given-names>MI</given-names></name><collab>EI-Sayed Amr</collab></person-group><article-title>Association of interleukin-2, interleukin-21 and interleukin-23 with hyperlipedemia in pediatric type 1 diabetes</article-title><source>Mol Bio Rep</source><year>2021</year><volume>48</volume><issue>7</issue><fpage>5421</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1007/s11033-021-06545-0</pub-id><pub-id pub-id-type="pmid">34328597</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">24, Khalil RG, Abdel-Moneim A, Yousef AI, Abdel-Rahman H, Zanaty MI, EI-Sayed Amr. Association of interleukin-2, interleukin-21 and interleukin-23 with hyperlipedemia in pediatric type 1 diabetes. Mol Bio Rep. 2021;48(7):5421&#8211;543.<pub-id pub-id-type="pmid">34328597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11033-021-06545-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kre&#946;</surname><given-names>L</given-names></name><name name-style="western"><surname>Egenolf</surname><given-names>N</given-names></name><name name-style="western"><surname>Sommer</surname><given-names>C</given-names></name><name name-style="western"><surname>&#220;&#199;eyler</surname><given-names>N</given-names></name></person-group><article-title>Cytokine expression profiles in white blood cells of patients with small fiber neuropathy</article-title><source>BMC Neurosci</source><year>2023</year><volume>24</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1186/s12868-022-00770-4</pub-id><pub-id pub-id-type="pmid">36604634</pub-id><pub-id pub-id-type="pmcid">PMC9817338</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">25, Kre&#946; L, Egenolf N, Sommer C, &#220;&#199;eyler N. Cytokine expression profiles in white blood cells of patients with small fiber neuropathy. BMC Neurosci. 2023;24:1&#8211;12.<pub-id pub-id-type="pmid">36604634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12868-022-00770-4</pub-id><pub-id pub-id-type="pmcid">PMC9817338</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nov</surname><given-names>O</given-names></name><name name-style="western"><surname>Kohl</surname><given-names>A</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>EC</given-names></name><name name-style="western"><surname>Bashan</surname><given-names>N</given-names></name><name name-style="western"><surname>Dvir</surname><given-names>I</given-names></name><name name-style="western"><surname>Ben-Shlomo</surname><given-names>S</given-names></name><etal/></person-group><article-title>Interleukin1b May mediate insulin resistance in liver-derived cells in response to adipocyte inflammation</article-title><source>Endocrinology</source><year>2010</year><volume>151</volume><fpage>4247</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1210/en.2010-0340</pub-id><pub-id pub-id-type="pmid">20660063</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">26, Nov O, Kohl A, Lewis EC, Bashan N, Dvir I, Ben-Shlomo S, et al. Interleukin1b May mediate insulin resistance in liver-derived cells in response to adipocyte inflammation. Endocrinology. 2010;151:4247&#8211;56.<pub-id pub-id-type="pmid">20660063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2010-0340</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>H</given-names></name><name name-style="western"><surname>Han</surname><given-names>L</given-names></name><name name-style="western"><surname>Ji</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>The preventive effect of IL-1beta antagonist on diabetic peripheral neuropathy</article-title><source>Endocr Metab Immune Disord Drug Targets</source><year>2020</year><volume>20</volume><issue>5</issue><fpage>753</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.2174/1871530319666191022114139</pub-id><pub-id pub-id-type="pmid">31642797</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">27, Zheng H, Han L, Ji L, Zhao W, Liu X, Zhang Q, et al. The preventive effect of IL-1beta antagonist on diabetic peripheral neuropathy. Endocr Metab Immune Disord Drug Targets. 2020;20(5):753&#8211;9.<pub-id pub-id-type="pmid">31642797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1871530319666191022114139</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sher</surname><given-names>EK</given-names></name><name name-style="western"><surname>Prnjavorac</surname><given-names>B</given-names></name><name name-style="western"><surname>Farhat</surname><given-names>EK</given-names></name><name name-style="western"><surname>Palic</surname><given-names>B</given-names></name><name name-style="western"><surname>Ansar</surname><given-names>S</given-names></name><name name-style="western"><surname>Sher</surname><given-names>F</given-names></name></person-group><article-title>Effect of diabetic neuropathy on reparative ability and immune response system</article-title><source>Mol Biotechnol</source><year>2023</year><pub-id pub-id-type="doi">10.1007/s12033-023-00813-z</pub-id><pub-id pub-id-type="pmid">37523019</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">28, Sher EK, Prnjavorac B, Farhat EK, Palic B, Ansar S, Sher F. Effect of diabetic neuropathy on reparative ability and immune response system. Mol Biotechnol. 2023. 10.1007/s12033-023-00813-z.<pub-id pub-id-type="pmid">37523019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12033-023-00813-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alfadul</surname><given-names>H</given-names></name><name name-style="western"><surname>Sabico</surname><given-names>S</given-names></name><name name-style="western"><surname>Al-Daghri</surname><given-names>NM</given-names></name></person-group><article-title>The role of interleukin-1&#946;in type 2 diabetes mellitus: a systematic review and meta-analysis</article-title><source>Front Endocrinol</source><year>2022</year><volume>2022</volume><fpage>901616</fpage><pub-id pub-id-type="doi">10.3389/fendo</pub-id><pub-id pub-id-type="pmcid">PMC9363617</pub-id><pub-id pub-id-type="pmid">35966098</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Alfadul H, Sabico S, Al-Daghri NM. The role of interleukin-1&#946;in type 2 diabetes mellitus: a systematic review and meta-analysis. Front Endocrinol. 2022;2022:901616. 10.3389/fendo.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2022.901616</pub-id><pub-id pub-id-type="pmcid">PMC9363617</pub-id><pub-id pub-id-type="pmid">35966098</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahgat</surname><given-names>MM</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>DR</given-names></name></person-group><article-title>Proinflammatory cytokine polarization in type a diabetes</article-title><source>Cent Eur J Immunol</source><year>2020</year><volume>45</volume><issue>2</issue><fpage>170</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.5114/ceji.2020.97904</pub-id><pub-id pub-id-type="pmid">33456327</pub-id><pub-id pub-id-type="pmcid">PMC7792447</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">30, Bahgat MM, Ibrahim DR. Proinflammatory cytokine polarization in type a diabetes. Cent Eur J Immunol. 2020;45(2):170&#8211;5.<pub-id pub-id-type="pmid">33456327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5114/ceji.2020.97904</pub-id><pub-id pub-id-type="pmcid">PMC7792447</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sokolova</surname><given-names>RN</given-names></name><name name-style="western"><surname>Yankova</surname><given-names>RK</given-names></name><name name-style="western"><surname>Abadjieva</surname><given-names>TI</given-names></name><name name-style="western"><surname>Popova</surname><given-names>TA</given-names></name><name name-style="western"><surname>Ivanovska</surname><given-names>MV</given-names></name><name name-style="western"><surname>Murdjeva</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Association between type 2 diabetes, obesity and key immunological components of Ig-E-mediated inflammation</article-title><source>Folia Med Plovdiv</source><year>2017</year><volume>59</volume><issue>2</issue><fpage>159</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1515/folmed-2017-0021</pub-id><pub-id pub-id-type="pmid">28704195</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">31, Sokolova RN, Yankova RK, Abadjieva TI, Popova TA, Ivanovska MV, Murdjeva MA, et al. Association between type 2 diabetes, obesity and key immunological components of Ig-E-mediated inflammation. Folia Med Plovdiv. 2017;59(2):159&#8211;64.<pub-id pub-id-type="pmid">28704195</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/folmed-2017-0021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nekoua</surname><given-names>MP</given-names></name><name name-style="western"><surname>Fachinan</surname><given-names>R</given-names></name><name name-style="western"><surname>Atchamou</surname><given-names>AK</given-names></name><name name-style="western"><surname>Nouatin</surname><given-names>O</given-names></name><name name-style="western"><surname>Amoussou-Guenou</surname><given-names>D</given-names></name><name name-style="western"><surname>Amoussou-Guenou</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Modulation of immune cells and Th1/Th2 cytokines in insulin-treated type 2 diabetes mellitus</article-title><source>Afr Health Sci</source><year>2016</year><volume>16</volume><issue>3</issue><fpage>714</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.4314/ahs.v16i3.11</pub-id><pub-id pub-id-type="pmcid">PMC5111983</pub-id><pub-id pub-id-type="pmid">27917204</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">32, Nekoua MP, Fachinan R, Atchamou AK, Nouatin O, Amoussou-Guenou D, Amoussou-Guenou MK, et al. Modulation of immune cells and Th1/Th2 cytokines in insulin-treated type 2 diabetes mellitus. Afr Health Sci. 2016;16(3):714&#8211;24.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4314/ahs.v16i3.11</pub-id><pub-id pub-id-type="pmcid">PMC5111983</pub-id><pub-id pub-id-type="pmid">27917204</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marino</surname><given-names>F</given-names></name><name name-style="western"><surname>Maresca</surname><given-names>AM</given-names></name><name name-style="western"><surname>Cosentino</surname><given-names>M</given-names></name><name name-style="western"><surname>Castiglioni</surname><given-names>L</given-names></name><name name-style="western"><surname>Rasini</surname><given-names>E</given-names></name><name name-style="western"><surname>Mongiardi</surname><given-names>C</given-names></name><etal/></person-group><article-title>Angiotensin II type 1 and type 2 receptor expression in Circulating monocytes of diabetic and hypercholesterolemic patients over 3-month Rosuvastatin treatment</article-title><source>Carduivascular Diabetol</source><year>2012</year><volume>11</volume><fpage>153</fpage><pub-id pub-id-type="doi">10.1186/1475-2840-11-153</pub-id><pub-id pub-id-type="pmcid">PMC3549933</pub-id><pub-id pub-id-type="pmid">23259529</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">33, Marino F, Maresca AM, Cosentino M, Castiglioni L, Rasini E, Mongiardi C, et al. Angiotensin II type 1 and type 2 receptor expression in Circulating monocytes of diabetic and hypercholesterolemic patients over 3-month Rosuvastatin treatment. Carduivascular Diabetol. 2012;11:153.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2840-11-153</pub-id><pub-id pub-id-type="pmcid">PMC3549933</pub-id><pub-id pub-id-type="pmid">23259529</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skyam</surname><given-names>A</given-names></name><name name-style="western"><surname>Gutlapalli</surname><given-names>VR</given-names></name><name name-style="western"><surname>Tenali</surname><given-names>SP</given-names></name><name name-style="western"><surname>Meena</surname><given-names>AK</given-names></name><name name-style="western"><surname>Chandran</surname><given-names>P</given-names></name><name name-style="western"><surname>Pratap</surname><given-names>DV</given-names></name><etal/></person-group><article-title>Association of tumor necrosis factor-alpha and interferon gamma gene polymorphisms and their plasma levels in leprosy, HIV and other peripheral neuropathies</article-title><source>Cytokine</source><year>2015</year><volume>76</volume><issue>2</issue><fpage>473</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2015.09.010</pub-id><pub-id pub-id-type="pmid">26431782</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">34, Skyam A, Gutlapalli VR, Tenali SP, Meena AK, Chandran P, Pratap DV, et al. Association of tumor necrosis factor-alpha and interferon gamma gene polymorphisms and their plasma levels in leprosy, HIV and other peripheral neuropathies. Cytokine. 2015;76(2):473&#8211;9.<pub-id pub-id-type="pmid">26431782</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cyto.2015.09.010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basol</surname><given-names>N</given-names></name><name name-style="western"><surname>Inanir</surname><given-names>A</given-names></name><name name-style="western"><surname>Yigit</surname><given-names>S</given-names></name><name name-style="western"><surname>Karakus</surname><given-names>N</given-names></name><name name-style="western"><surname>Kaya</surname><given-names>SU</given-names></name></person-group><article-title>High association of IL-4 gene intron 3 VNTR polymorphism with diabetic peripheral neuropathy</article-title><source>J Mol Neurosci</source><year>2013</year><volume>51</volume><issue>2</issue><fpage>437</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1007/s12031-013-0048-y</pub-id><pub-id pub-id-type="pmid">23771787</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">35, Basol N, Inanir A, Yigit S, Karakus N, Kaya SU. High association of IL-4 gene intron 3 VNTR polymorphism with diabetic peripheral neuropathy. J Mol Neurosci. 2013;51(2):437&#8211;41.<pub-id pub-id-type="pmid">23771787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12031-013-0048-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">36, Zhong J, Lin X, Zheng X, Zhou Y, Huang H, Xu L. Diminished levels of insulin-like growth factor &#8211;&#8201;1 May be a risk factor for peripheral neuropathy in type 2 diabetes patients. J Diabetes Investig. 2024. 10.1111/jdi.14260.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jdi.14260</pub-id><pub-id pub-id-type="pmcid">PMC11363116</pub-id><pub-id pub-id-type="pmid">38923403</pub-id></mixed-citation></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aghanoori</surname><given-names>MR</given-names></name><name name-style="western"><surname>Smith</surname><given-names>DR</given-names></name><name name-style="western"><surname>Sharuatu-Levari</surname><given-names>S</given-names></name><name name-style="western"><surname>Ajisebutu</surname><given-names>A</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>A</given-names></name><name name-style="western"><surname>Desmond</surname><given-names>F</given-names></name><etal/></person-group><article-title>Insulin-like growth factor-1 activates AMPK to augment mitochondrial function and correct neuronal metabolism in sensory neurons in type 1 diabetes</article-title><source>Mol Metabolism</source><year>2019</year><volume>20</volume><fpage>149</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.molmet.2018.11.008</pub-id><pub-id pub-id-type="pmcid">PMC6358538</pub-id><pub-id pub-id-type="pmid">30545741</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">37, Aghanoori MR, Smith DR, Sharuatu-Levari S, Ajisebutu A, Nguyen A, Desmond F, et al. Insulin-like growth factor-1 activates AMPK to augment mitochondrial function and correct neuronal metabolism in sensory neurons in type 1 diabetes. Mol Metabolism. 2019;20:149&#8211;65.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmet.2018.11.008</pub-id><pub-id pub-id-type="pmcid">PMC6358538</pub-id><pub-id pub-id-type="pmid">30545741</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andersen</surname><given-names>ST</given-names></name><name name-style="western"><surname>Witte</surname><given-names>DR</given-names></name><name name-style="western"><surname>Dalsgaard</surname><given-names>EM</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>H</given-names></name><name name-style="western"><surname>Nawroth</surname><given-names>P</given-names></name><name name-style="western"><surname>Fleming</surname><given-names>T</given-names></name><etal/></person-group><article-title>Risk factors for incident diabetic polyneuropathy in a cohort with screen-detected type 2 diabetes followed for 13 years: ADDITION-Denmark</article-title><source>Diabetes Care</source><year>2018</year><volume>41</volume><issue>5</issue><fpage>1068</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.2337/dc17-2062</pub-id><pub-id pub-id-type="pmid">29487078</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">38, Andersen ST, Witte DR, Dalsgaard EM, Andersen H, Nawroth P, Fleming T, et al. Risk factors for incident diabetic polyneuropathy in a cohort with screen-detected type 2 diabetes followed for 13 years: ADDITION-Denmark. Diabetes Care. 2018;41(5):1068&#8211;75.<pub-id pub-id-type="pmid">29487078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc17-2062</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Christensen</surname><given-names>DH</given-names></name><name name-style="western"><surname>Knudsen</surname><given-names>ST</given-names></name><name name-style="western"><surname>Gylfadottir</surname><given-names>SS</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>LB</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>JS</given-names></name><name name-style="western"><surname>Beck-Nielsen</surname><given-names>H</given-names></name><etal/></person-group><article-title>Metabolic factors, lifestyle habits, and possible polyneuropathy in early type 2 diabetes: a nationwide study of 5,249 patients in the Danish centre for strategic research in type 2 diabetes (DD2) cohort</article-title><source>Diabetes Care</source><year>2020</year><volume>43</volume><issue>6</issue><fpage>1266</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.2337/dc19-2277</pub-id><pub-id pub-id-type="pmid">32295810</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">39, Christensen DH, Knudsen ST, Gylfadottir SS, Christensen LB, Nielsen JS, Beck-Nielsen H, et al. Metabolic factors, lifestyle habits, and possible polyneuropathy in early type 2 diabetes: a nationwide study of 5,249 patients in the Danish centre for strategic research in type 2 diabetes (DD2) cohort. Diabetes Care. 2020;43(6):1266&#8211;75.<pub-id pub-id-type="pmid">32295810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc19-2277</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Callaghan</surname><given-names>BC</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>E</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Kerber</surname><given-names>K</given-names></name><name name-style="western"><surname>Pop-Busui</surname><given-names>R</given-names></name><name name-style="western"><surname>Moffet</surname><given-names>H</given-names></name><etal/></person-group><article-title>Triglycerides and amputation risk in patients with diabetes: ten-year followup in the DISTANCE study</article-title><source>Diabetes Care</source><year>2011</year><volume>34</volume><issue>3</issue><fpage>635</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.2337/dc10-0878</pub-id><pub-id pub-id-type="pmid">21285390</pub-id><pub-id pub-id-type="pmcid">PMC3041196</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">40, Callaghan BC, Feldman E, Liu J, Kerber K, Pop-Busui R, Moffet H, et al. Triglycerides and amputation risk in patients with diabetes: ten-year followup in the DISTANCE study. Diabetes Care. 2011;34(3):635&#8211;40.<pub-id pub-id-type="pmid">21285390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc10-0878</pub-id><pub-id pub-id-type="pmcid">PMC3041196</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reynolds</surname><given-names>EL</given-names></name><name name-style="western"><surname>Akinci</surname><given-names>G</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>M</given-names></name><name name-style="western"><surname>Looker</surname><given-names>HC</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>A</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>RG</given-names></name><etal/></person-group><article-title>The determinants of complication trajectories in American Indians with type 2 diabetes</article-title><source>JCI Insight</source><year>2021</year><volume>6</volume><issue>10</issue><fpage>e146849</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.146849</pub-id><pub-id pub-id-type="pmid">34027894</pub-id><pub-id pub-id-type="pmcid">PMC8262294</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">41, Reynolds EL, Akinci G, Banerjee M, Looker HC, Patterson A, Nelson RG, et al. The determinants of complication trajectories in American Indians with type 2 diabetes. JCI Insight. 2021;6(10):e146849.<pub-id pub-id-type="pmid">34027894</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/jci.insight.146849</pub-id><pub-id pub-id-type="pmcid">PMC8262294</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barter</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Nicholls</surname><given-names>S</given-names></name><name name-style="western"><surname>Rye</surname><given-names>KA</given-names></name><name name-style="western"><surname>Anantharamaiah</surname><given-names>GM</given-names></name><name name-style="western"><surname>Navab</surname><given-names>M</given-names></name><name name-style="western"><surname>Fogelman</surname><given-names>AM</given-names></name></person-group><article-title>Antiinflammatory properties of HDL</article-title><source>Circ Res</source><year>2004</year><volume>95</volume><fpage>764</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000146094.59640.13</pub-id><pub-id pub-id-type="pmid">15486323</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">42, Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res. 2004;95:764&#8211;72.<pub-id pub-id-type="pmid">15486323</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.RES.0000146094.59640.13</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>A</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X</given-names></name><name name-style="western"><surname>Ding</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name></person-group><article-title>Low serum apolipoprotein A1/B ratio is associated with proliferative diabetic retinopathy in type 2 diabetes</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>2012</year><volume>250</volume><fpage>957</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1007/s00417-011-1855-x</pub-id><pub-id pub-id-type="pmid">22327732</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">43, Hu A, Luo Y, Li T, Guo X, Ding X, Zhu X. Low serum apolipoprotein A1/B ratio is associated with proliferative diabetic retinopathy in type 2 diabetes. Graefes Arch Clin Exp Ophthalmol. 2012;250:957&#8211;62.<pub-id pub-id-type="pmid">22327732</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00417-011-1855-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aryan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Afarideh</surname><given-names>M</given-names></name><name name-style="western"><surname>Ghajar</surname><given-names>A</given-names></name><name name-style="western"><surname>Esteghamati</surname><given-names>A</given-names></name><name name-style="western"><surname>Nakhjavani</surname><given-names>M</given-names></name></person-group><article-title>Conflicting interactions of Apolipoprotein A and high density lipoprotein cholesterol with microvascular complications of type 2 diabetes</article-title><source>Diabetes Res Clin Pract</source><year>2017</year><volume>133</volume><fpage>131</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2017.07.037</pub-id><pub-id pub-id-type="pmid">28934670</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">44, Aryan Z, Afarideh M, Ghajar A, Esteghamati A, Nakhjavani M. Conflicting interactions of Apolipoprotein A and high density lipoprotein cholesterol with microvascular complications of type 2 diabetes. Diabetes Res Clin Pract. 2017;133:131&#8211;41.<pub-id pub-id-type="pmid">28934670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2017.07.037</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>CS</given-names></name><name name-style="western"><surname>Pai</surname><given-names>YW</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>IT</given-names></name><name name-style="western"><surname>Chang</surname><given-names>MH</given-names></name></person-group><article-title>Renal impairment is one of appropriate predictors of future diabetic peripheral neuropathy: a hospital-based 6-year follow-up study</article-title><source>Sci Rep</source><year>2022</year><volume>28</volume><issue>1</issue><fpage>5240</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-09333-3</pub-id><pub-id pub-id-type="pmcid">PMC8960825</pub-id><pub-id pub-id-type="pmid">35347201</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">45, Wang CS, Pai YW, Lin CH, Lee IT, Chang MH. Renal impairment is one of appropriate predictors of future diabetic peripheral neuropathy: a hospital-based 6-year follow-up study. Sci Rep. 2022;28(1):5240.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-022-09333-3</pub-id><pub-id pub-id-type="pmcid">PMC8960825</pub-id><pub-id pub-id-type="pmid">35347201</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferguson</surname><given-names>TW</given-names></name><name name-style="western"><surname>Komenda</surname><given-names>P</given-names></name><name name-style="western"><surname>Tangri</surname><given-names>N</given-names></name></person-group><article-title>Cystatin C as a biomarker for estimating glomerular filtration rate</article-title><source>Curr Opin Nephrol Hypertens</source><year>2015</year><volume>24</volume><fpage>295</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1097/MNH.0000000000000115</pub-id><pub-id pub-id-type="pmid">26066476</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">46, Ferguson TW, Komenda P, Tangri N. Cystatin C as a biomarker for estimating glomerular filtration rate. Curr Opin Nephrol Hypertens. 2015;24:295&#8211;300.<pub-id pub-id-type="pmid">26066476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MNH.0000000000000115</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>47</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shen</surname><given-names>F</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name></person-group><article-title>Association between serum Cystatin C and diabetic peripheral neuropathy: a cross-sectional study of a Chinese type 2 diabetic population</article-title><source>Eur J Endocrinol</source><year>2014</year><volume>171</volume><issue>5</issue><fpage>641</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1530/EJE-14-0381</pub-id><pub-id pub-id-type="pmid">25184282</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Hu 47, Liu Y, Shen F, Zeng J, Li H, Zhao L. Association between serum Cystatin C and diabetic peripheral neuropathy: a cross-sectional study of a Chinese type 2 diabetic population. Eur J Endocrinol. 2014;171(5):641&#8211;8.<pub-id pub-id-type="pmid">25184282</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1530/EJE-14-0381</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>